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CHARACTERIZING A NOVEL ROLE FOR THE NOCICEPTIN SYSTEM IN BRAIN
DEVELOPMENT
By Logan Meyer
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Major Director: Carmen Sato-Bigbee, Ph.D.
Associate Professor, Department of Biochemistry and Molecular Biology

Our previous results showed that oligodendrocyte development is regulated
by both nociceptin and its G-protein coupled receptor, the nociceptin/orphanin FQ
receptor (NOPR). The present in vitro and in vivo findings show that nociceptin plays
a crucial conserved role in both human and rodent brain astrocytes, regulating the
levels of the glutamate/aspartate transporter GLAST/EAAT1. This nociceptinmediated response takes place during a critical developmental window that coincides
with astrocyte maturation and synapse formation. GLAST/EAAT1 upregulation by
nociceptin is mediated by NOPR and the downstream participation of a complex
xvii

signaling cascade that involves the interaction of several kinase systems, including PI3K/AKT, mTOR and JAK. Because GLAST is the main glutamate transporter during
brain maturation, these novel findings suggest that nociceptin plays a crucial role in
regulating the function of early astrocytes and their capacity to support glutamate
homeostasis in the developing brain.

xviii

Introduction
Nociceptin is an endogenous heptadecapeptide (Figure 1.1) that selectively and with
high affinity binds to the nociceptin receptor (NOPR) or opioid receptor like-1 (ORL1), the
most recently discovered member of the opioid receptor family. Previous results from our
laboratory showed that NOPR plays a role in oligodendrocyte development perhaps
preventing precocious brain myelination (Eschenroeder et al., 2012). While several roles
for the classical opioid receptors in central nervous system (CNS) maturation have been
described, this was one of the first implications of NOPR in brain development.
Furthermore, the studies presented in this thesis showed that NOPR is also found in
astrocytes. Our results indicated that nociceptin plays an important role in maturing
rodent and human astrocytes, stimulating the expression of the glutamate transporter
GLAST/EAAT1. These findings suggest that the nociceptin system may not only control
myelination, but also play a critical function in glutamate homeostasis in the developing
brain. This function appears to be restricted to a crucial period of astrocyte generation that
coincides with an active window of synapse formation.

Thus, the following section

concentrates on the origin and functions of these important glial cells.

Astrocytes in brain development

1

Figure 1.1 Nociceptin. Nociceptin is a 17-amino acid endogenous peptide with high
similarity to the endogenous opioid Dynorphin A.

2

3

Brain development is carefully controlled by a number of precisely timed events from
the proliferation of neuroblasts to the pruning of synapses and myelination.

While it is

now known that glia play a number of critical roles in the correct execution of this timeline,
these cells were long thought to function as no more than simple support for neurons,
providing trophic help and protection. However, the development of experimental tools
like primary glial cell culture, patch-clamp electrophysiology, and fluorescent calcium dyes
allowed further investigation that uncovered a wide range of unsuspected astrocyte
functions. In the mid-1980’s, it was discovered that astrocytes express receptors for the
neurotransmitter γ-amino butyric acid (GABA) (Backus et al., 1988; Hösli and Hösli, 1990a;
b; Magoski et al., 1992) When activated, these receptors could produce calcium waves able
to disseminate over long distances. This was the first indication that astrocytes were not
only electrically active but could also respond to the same molecules that were released
from neurons during synaptic transmission (Charles et al., 1991; Dani et al., 1992).
Furthermore, it was demonstrated that the neurotransmitter-induced calcium waves in
astrocytes could eventually generate calcium waves in neurons (Nedergaard, 1994;
Parpura et al., 1994).

These results strengthened the concept that astrocytes were not

simply ‘glue’ but respond to and significantly influence brain chemistry and information
processing (Cornell-Bell et al., 1990; Nedergaard, 1994; Parpura et al., 1994)
The number of functions attributed to astrocytes is ever increasing including
regulation of neuronal activity (Halassa and Haydon, 2010), brain glycogen storage and
energy production (Pellerin and Magistretti, 1994; Brown and Ransom, 2007), water
distribution (Nielsen et al., 1997), antioxidant metabolism (Aschner, 2000), ion buffering
4

(Bevan et al., 1985; Bordey and Sontheimer, 2000), and induction and maintenance of the
blood brain barrier (Janzer and Raff, 1987; Hawkins and Davis, 2005).

Specifically in

brain development, astrocytes contribute to a number of events ranging from cell
proliferation and differentiation to migration and synaptogenesis. The following sections
will discuss some of these developmental functions and the molecules that regulate them.

Proliferation and differentiation of neural progenitors
Neurons, astrocytes and oligodendrocytes in the brain arise from a single cell type
known as neural stem cell (NSC). While a pool of NSCs is maintained through proliferation,
a subpopulation of these cells undergoes a specific transformation that produces radial glia
cells, a bipolar cell spanning the cortex (Figure 1.2). Asymmetrical division of these radial
glia cells generates neuron-, oligodendrocyte-, and astrocyte-specific intermediate
progenitor cells (nIPCs, oIPCs, and aIPCs) (Williams et al., 1991; Grove et al., 1993; Reid et
al., 1995; Williams and Price, 1995; Merkle and Alvarez-Buylla, 2006). From the pool of
IPCs, the first cell type to appear in the brain is neurons followed by astrocytes and finally
oligodendrocytes.
Furthermore, much like NSCs, radial glia cells continue to proliferate while
maintaining cell bodies in the ventricular zone (VZ), the main site of neurogenesis,
throughout cortical development (Mission et al., 1991). Interestingly, during this time
radial glia cells express a number of astrocyte markers like the glutamate/aspartate
transporter (GLAST), brain lipid binding protein (BLBP), and the intermediate filament
protein glial fibrillary acidic protein (GFAP) (Levitt and Rakic, 1980; Shibata et al., 1997).
5
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Figure 1.2 Timeline of rat brain cell development. Neural stem cells undergo both
symmetric and asymmetric divisions, which produce radial glia cells. Radial glia cells
originate neuron, astrocyte and oligodendrocyte specific progenitor cells, nIPCs, aIPCs,
oIPCS.

These intermediate progenitors likely proliferate for a period of time before

entering terminal differentiation. At the end of neurogenesis, most radial glia will detach
from the VZ and transform into astrocytes. VZ=ventricular zone, SVZ=subventricular zone,
IZ=intermediate zone, CP=cortical plate, MZ=marginal zone. Adapted from Kriegstein and
Alvarez-Bullya, 2009.
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By the end of cortical development, the majority of radial glial cells have transformed into
astrocytes. However, a small number of radial glia will remain in the VZ and subventricular
zone (SVZ) as adult neural stem cells (Voigt, 1989; Culican et al., 1990; Merkle et al., 2004).

Astrocytes and their role in cell migration
In addition to being cell precursors, astrocytes and radial glia serve as a scaffold upon
which neurons migrate during brain development toward the cortical plate and pia mater.
Migration is controlled by interactions between secreted and cell surface proteins and
receptors present in the neuronal precursors as well as the radial glia. These interactions
control many aspects from adhesion and attraction to migration and repulsion.

For

example, expression of adhesion molecules like β1 integrins in radial glia cells is necessary
for the outgrowth of radial glia fibers, a critical step in the correct formation of the layered
regions of the brain (Graus-Porta et al., 2001; Belvindrah et al., 2007). Furthermore, the
β1α3 integrin is a co-receptor for reelin, a molecule expressed in migrating neuronal
precursors, that regulates migration end points (Anton et al., 1999; Dulabon et al., 2000;
Graus-Porta et al., 2001; Schmid et al., 2004; Belvindrah et al., 2007).
Another important migration signal is the neurotransmitter glutamate. Komuro and
Rakic showed that blocking two different glutamate receptors, the N-methyl-d-aspartate
(NMDA) and the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA/Kainate)
receptors, on the neuronal precursors significantly slowed migration (Komuro and Rakic,
1993; Manent, 2006; Jansson et al., 2013; Jansson and Akerman, 2014; Luhmann et al.,
2015). Furthermore, glutamate was shown to be a powerful chemoattractant (Behar et al.,
8

1999; Manent, 2006; Manent and Represa, 2007). Importantly, the extracellular
concentration of this neurotransmitter is modulated by astrocytes and radial glia through
the glutamate/aspartate protein mentioned earlier, GLAST, further demonstrating the
critical role of astrocytes and radial glia in neuronal migration (Behar et al., 1999). In
addition to serving as the scaffold for neurons, radial glia cells also serve as migratory
pathways for aIPCs and oIPCS (Culican et al., 1990). Once the progenitors have migrated to
their final location they will continue to proliferate until the brain is populated (Ge et al.,
2012). When astrocytes reach their final locations a number of signals, as detailed in the
next section, control their differentiation.

Astrocyte development
While the differentiation of oligodendrocytes and neurons proceeds in clearly defined
steps with distinct markers, the effort to understand whether astrocyte maturation follows
a similar step-wise pattern has been impeded by the heterogeneity of this glial cell
population and a lack of specific maturational markers (Molofsky and Deneen, 2015).
However, much of what is known about the switch from neurogenesis to gliogenesis was
gathered during a very narrow window at the end of neurogenesis around embryonic day
16-18 (E16-E18), during which a ‘gliogenic switch’ occurs that leads to astrocyte
generation in the cortex. In this critical window it was discovered that both extracellular
and intrinsic factors play important roles in the transition from neuro- to gliogenesis.
Extracellular factors such as ciliary neurotrophic factor (CNTF), leukemia inhibitory factor
(LIF) (Johe et al., 1996; Bonni et al., 1997), and cardiotrophin-1 (CT-1) (Barnabé-Heider et
9

al., 2005) were shown to push progenitors toward an astrocyte lineage by initiating
signaling cascades that induce the expression of typical astrocytic genes like GFAP, GLAST
and glutamine synthetase (He et al., 2005).
Intrinsically, epigenetic mechanisms including the methylation of key pro-neuronal
genes and demethylation of pro-astrocytic genes are critical steps during the gliogenic
switch. Due to an open chromatin conformation, the pro-neuronal genes neurogenin 1 and
2, whose expression is mediated by wnt signaling, are highly expressed during
neurogenesis. As the gliogenic switch occurs, the methylation of neurogenin genes
increases and therefore, despite no change in expression of wnt ligands, neurogenin
expression levels in neurons decrease (Namihira et al., 2004; Hirabayashi et al., 2009).
Furthermore, an increase in CT-1 secretion from neurogenin-positive neurons activates the
JAK/STAT cascade in neural progenitors. Downstream of these signals, Nuclear Factor I-A
(NFIA), an inhibitor of DNA methyltransferase 1 (DNMT1) is activated, relieving the
methylation of pro-astrocytic genes and subsequently increasing their expression
(Takizawa et al., 2001; Namihira et al., 2004, 2009; Deneen et al., 2006). It was later shown
that Sox9 was critical to astrocytogenesis as this transcription factor not only induces the
expression of NFIA but also forms an essential gene regulatory complex later in gliogenesis
(Kang et al., 2012).

Interestingly, despite neurogenesis being established prior to the

generation of astrocytes, the formation of synapses is delayed until gliogenesis has begun
(Figure 1.3). The reasons for this sequence of events underscore the importance of
astrocytes in brain development and will be explained in the following section.

10

Astrocytes and synaptogenesis
Studies in the rodent and human brain indicated that while neurons develop at early
embryonic age synaptogenesis does not proceed until gliogenesis begins during the late
embryonic stages and parallels astrocyte generation well into postnatal development (Fig.
1.3) (Slezak and Pfrieger, 2003). These observations led to the discovery that astrocytes
play a role in all of the major steps of synaptogenesis, including, the initial contact between
pre- and postsynaptic neurons, as well as synapse maturation, stabilization and
elimination. Pfrieger and Barres showed that in culture, neurons alone formed synapses
very slowly. However, synapse formation increased 7-fold when neurons were co-cultured
with astrocytes (Pfrieger and Barres, 1997). A number of factors synthesized and secreted
by astrocytes that influence synaptogenesis were later discovered, such as the family of
large extracellular matrix (ECM) proteins known as the thrombospondins (TSPs). It was
shown that TSP expression in the brain reaches a peak during the early postnatal period
when synaptogenesis is also at the highest. Notably, addition of TSP1 and TSP2 to neuronal
cultures resulted in a dramatic 7-fold increase in synapse formation, similar to the level of
synapse induction previously observed in astrocyte-neuron co-cultures or neuronal
cultures treated with astrocyte-conditioned medium (ACM) (Christopherson et al., 2005).
Investigation into the mechanisms underlying these effects found that TSPs recruit
scaffolding proteins and initiate synaptic adhesion through interactions with voltage-gated
calcium channels on neurons (Eroglu et al., 2008, 2009).
Interestingly, the influence of TSPs on synapse formation appears to be purely physical
because the synapses created under the influence of these molecules alone are not
11

Figure 1.3 Timeline of developmental events. (A). Neuronal proliferation and migration
occur prenatally in human brains.

Gliogenesis and synaptogenesis begin almost

simultaneously at around 16-18 weeks of gestation and continue well into postnatal brain
development. Myelination begins in the third trimester and continues throughout early
childhood and adolescence. (B) Similar to human brain development, rat neuronal
proliferation and migration occur completely prenatally.

In contrast, the bulk of

gliogenesis and synaptogenesis occurs in early postnatal development. Furthermore, all of
myelination occurs in the postnatal brain.
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electrically active. However, the “activation” of these neurons is also regulated by
astrocyte-secreted molecules which induce the expression of a number of receptors on the
postsynaptic densities (Eroglu et al., 2008; Eroglu and Barres, 2010). Glypican 4 and 6, a
set of astrocytic proteoglycans, are able to increase the frequency and amplitude of
synaptic events. These ECM proteins increase cell surface expression of the GluA1 subunit
of the AMPA receptor in retinal ganglion neurons. Furthermore, glypican 6 was shown to
induce NMDA receptor-mediated calcium currents through a similar mechanism in neurons
induced from human pluripotent stem cells (Allen et al., 2012; Sato et al., 2016). In addition
to ECM proteins, astrocytic expression of cytokines like transforming growth factor-β (TGFβ) increases the expression of TSP1 therefore helping to stabilize synapses. Additionally,
TGF-β is able to induce excitatory signaling by raising the extracellular concentration of dserine, an NMDA receptor co-agonist (Diniz et al., 2012). Modulation of neurotransmitter
levels is one of the hallmark functions of astrocytes and constitutes one of the most critical
roles of these glial cells in the synapse. Therefore, the next section will focus on the
influence of astrocytes in synaptic transmission specifically as components of what is now
known as the “tripartite” synapse.

Astrocytes in the tripartite synapse
The classical idea of a synapse involves two neurons, a pre-synaptic one that releases
neurotransmitters, which then bind to receptors expressed on the postsynaptic neuron.
Previously, astrocytes have been shown to modulate neuronal activity by providing energy
and maintaining extracellular ion concentrations and pH (Bevan et al., 1985; Pellerin and
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Magistretti, 1996; Nielsen et al., 1997). However, it is now understood that astrocytes play
a more active and important role in synaptic transmission. Interestingly, ultrastructural
analyses from the 1950’s showed that astrocytes intimately surrounded many synapses, an
observation which later lent support to the idea of an astrocytic role in synaptic
transmission (Luse, 1956; Schultz et al., 1957).
It was not until the discovery of neurotransmitter-induced intracellular calcium waves in
astrocytes that it was suggested these cells might play a larger role in synaptic signaling.
As mentioned previously, two separate laboratories showed that inducing calcium
oscillations in a single astrocyte prompted changes in the intracellular calcium
concentrations of the surrounding neurons (Nedergaard, 1994; Parpura et al., 1994). These
discoveries led to the concept of the “tripartite synapse”, defined as a multidirectional
signaling system between neurons and astrocytes, in which these glial cells are able to both
respond and influence synaptic activity (Perea et al., 2009).
The inclusion of astrocytes as equipotent members of the synapse was contingent on
their ability to demonstrate the same or similar functions to those exhibited by neurons.
For example, while astrocytes do not exhibit traditional electrical excitation like neurons;
the propagated calcium oscillations seen both intracellularly and intercellularly, fulfill this
excitation requirement (Nedergaard, 1994; Parpura et al., 1994; Araque et al., 1998;
Schipke et al., 2008). Moreover, the expression of a number of receptors, including
metabotropic and ionotropic glutamate receptors (Jabs et al., 1994; Steinhäuser et al.,
1994; Porter and McCarthy, 1995, 1996) , as well as GABA (Hösli and Hösli, 1990a; b;
Steinhäuser et al., 1994; Fraser et al., 1995), and adrenergic receptors (Duffy and MacVicar,
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1995) allows astrocytes to mount unique responses to different neurotransmitters
(Schipke et al., 2008; Parri et al., 2010). Finally, like neurons, astrocytes are able to
integrate different stimuli into a single response, as evidenced by the fact that the
frequency of the calcium wave generated in astrocytes is not necessarily proportional to
the level of synaptic activity to which they are responding (Perea and Araque, 2005, 2006).
Together, these qualities of astrocytes: unique responses to activation by different
neurotransmitter receptors, calcium oscillations in response to synaptic activity, and a nonlinear integration of signals, indicate that astrocytes are active members of the synapse.
Furthermore, astrocytes are not only able to respond to neurons but are also capable of
directly influencing neuronal activity. Neurotransmitters exocytosed from astrocytes are
able to bind to receptors on pre- and postsynaptic densities and elicit an effect (Parpura
and Haydon, 2000; Pasti et al., 2001). For example, glutamate produced by astrocytes can
bind to metabotropic glutamate receptors in presynaptic neurons and affect the vesicular
release of neurotransmitters. Astrocyte-released d-Serine, an NMDA receptor co-agonist,
binds at postsynaptic neurons and controls receptor activation (Araque et al., 1998; Kang
et al., 1998; Yang et al., 2003; Fiacco and Mccarthy, 2004; Jourdain et al., 2007;
Henneberger et al., 2010). These astrocyte-released neurotransmitters, termed
“gliotransmitters”, as well as the astrocytic regulation of both glio- and neurotransmitters
will be the focus of the next section.

Astrocytes, neurotransmitters, and gliotransmitters
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Astrocytes also have the ability to synthesize and secrete a number of neuroactive
compounds or “gliotransmitters”.

These gliotransmitters range from common

neurotransmitters such as acetylcholine, GABA (Lee et al., 2011), glutamate (Bezzi et al.,
1998; Jourdain et al., 2007), d-serine (Snyder and Kim, 2000), dopamine (Oliva et al., 2013),
and glycine (Shibasaki et al., 2016) as well as others including ATP (Fields and Stevens,
2000; Kang et al., 2008), small peptides, a number of neurotrophins, growth factors, and
cytokines, both pro- and anti-inflammatory (Bezzi et al., 1998; Duan et al., 2003; Bergami et
al., 2008). The release mechanisms for many of these molecules remain unidentified.
However, it is known that the vesicular release of glutamate and d-serine is calciumdependent and very similar to their exocytosis from neurons. The activation of a number of
different astrocyte cell surface proteins, like metabotropic glutamate receptors, ion
channels, and G-protein coupled receptors (GPCRs), causes an increase in the
concentration of intracellular calcium and facilitate vesicular fusion via a SNAREdependent mechanism (Montana et al., 2006; Parpura and Zorec, 2010).
Interestingly, there are also a number of calcium-independent mechanisms like
activation of anion channels (Kimelberg et al., 1990; Mongin and Kimelberg, 2002),
purinergic receptors (Kukley et al., 2001; Duan et al., 2003), hemichannels (Cotrina et al.,
1998; Stout et al., 2002; Ye et al., 2003), and reversal of transporters (Szatkowski et al.,
1990; Attwell et al., 1993; Longuemare and Swanson, 1997; Bender et al., 2000; Rossi et al.,
2000; Allen et al., 2001; Baker et al., 2002; Re et al., 2006). The regulation of neuro- and
gliotransmitters by astrocytes is critical as they have concentration-dependent functions
both in the adult brain and in development. Furthermore, as critical components of the
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synapse and key regulators of neurotransmitters, it is logical that dysfunction in astrocytes
could lead to neurological disorders characterized by altered excitability. The following
section will investigate the roles of astrocytes in a common hyperexcitability disorder,
epilepsy.

Astrocytes and seizures
Normal brain activity is non-synchronous, meaning that excitatory and inhibitory
neurons are activated sequentially, therefore avoiding over activation of the neurons in
certain areas of the brain. In addition to inhibitory neurons, activation of voltage-gated and
calcium-dependent potassium currents as well as binding of adenosine to its receptors all
contribute to the maintenance of non-synchronous activity. Seizures are characterized by a
paroxysmal-depolarizing shift, where the non-synchronous activity turns into the
synchronous firing of multiple excitatory neurons at once (Lomen-Hoerth, 2013).
Hyperexcitability in the brain can result from a loss of inhibitory interneurons or increased
extracellular accumulation of potassium, causing depolarization of surrounding neurons.
Additionally, repeated depolarization relieves the magnesium block associated with NMDA
receptors therefore increasing calcium influx into postsynaptic densities resulting in
increased vesicular fusion and neurotransmission (Lomen-Hoerth, 2013). Furthermore,
repairing of the neuronal death that occurs during seizures, can create areas prone to
hyperexcitability due to the uneven neurogenesis of excitatory and inhibitory synapses, an
event that has been shown to be modulated by opioids (see section on Opioids and
Development) (Pitkänen and Lukasiuk, 2009). Based on this, the current targets for
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treatment in epilepsy are inhibition of ion channels to reduce neurotransmission or
enhancement of the function of GABA, the most common inhibitory neurotransmitter.
While seizures are often associated with epilepsy, they can be caused by a number of
triggers such as morphine overdose, traumatic brain injury, and high fever (Delanty et al.,
1998; Westbrook et al., 1998). Furthermore, hyperexcitability is a hallmark of a number of
neuropsychiatric diseases like schizophrenia (Benes, 2000; Lewis and Gonzalez-Burgos,
2000), Tourette’s syndrome (Orth and Rothwell, 2009; Draper et al., 2014), post-traumatic
stress disorder (PTSD) (Centonze et al., 2005), anxiety and autism (Chao et al., 2010).

As mentioned previously, astrocytes have many roles in the brain one of them being
maintenance of correct extracellular levels of certain ions, for example, potassium.
Interestingly, during seizures extracellular potassium levels increase about 4-fold, a level
sufficient to generate epileptiform activity (Heinemann and Lux, 1977; Rutecki et al., 1985).
Extracellular potassium levels are controlled by inward-rectifying potassium (Kir) channels
present in astrocytes. Decreased expression of these channels leads to impaired potassium
buffering and increased chances of seizures (Djukic et al., 2007; Seifert et al., 2009; HajYasein et al., 2011). Moreover, a missense mutation in Kir4.1 in humans is linked to
increased seizure susceptibility (Buono et al., 2004).
Furthermore, astrocytes express aquaporin 4 (Aqp4), a water channel that regulates
the entry of water into the brain and extracellular space. During temporal lobe epilepsy
(TLE), while there is no overall loss of Aqp4, redistribution of this channel away from the
perivascular space occurs disturbing the water flux and therefore ionic concentration in the
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brain (Eid et al., 2005). Interestingly, loss of perivascular Aqp4 expression was observed in
a kainic acid epilepsy model, suggesting that both impaired water and potassium regulation
contribute to neuronal hyperexcitability in this disease (Medici et al., 2011; Lee et al.,
2012). However, one of the most significant roles for astrocytes in epilepsy is the ability to
modulate extracellular concentrations of glutamate, the main excitatory neurotransmitter
in the CNS. The following sections will focus on the glutamate transporters that are
responsible for this astroglial function, critical under both normal and pathological
conditions.

Glutamate and Glutamate Transporters
As the major excitatory neurotransmitter in the CNS, glutamate activates the ionotropic
NMDA, AMPA, and kainate receptors as well as the metabotropic glutamate receptors or
mGluRs. However, excess glutamate can also exert excitotoxic effects. Overactivation of
ionotropic receptors by abnormally high levels of glutamate can result in an excessive
increase in intracellular calcium and activation of enzymes leading to apoptotic cell death
of both neurons (Lucas and Newhouse, 1957; Choi, 1988; Ankarcrona et al., 1995) and
oligodendrocytes (Domercq et al., 2005; Matute et al., 2007). Because high levels of
neurotransmitter are necessary for activation of glutamate receptors in the postsynaptic
density, a system of transporters is required to rapidly and effectively remove excessive
glutamate from the synaptic cleft. The following sections will expand on the role of
astrocytes in regulating glutamate levels through the expression of specific transporters
that are at the center of the studies in this thesis work.
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Astrocytic regulation of extracellular glutamate levels
Normally, neurotransmission is terminated in one of two ways, rapid degradation of the
neurotransmitter or rapid neurotransmitter removal from the synapse.

For some

neurotransmitters this function is executed by a hydrolyzing enzyme; such is the case of
acetylcholinesterase, the enzyme that terminates cholinergic signaling by causing rapid
breakdown of acetylcholine in the synapse.

However, unlike acetylcholine, glutamate is

quickly transported out of the synapse. This removal process is reliant on a family of
sodium-dependent glutamate transporters that are capable of cellular internalization of
glutamate and aspartate from the extracellular space. These so called Excitatory Amino
Acid Transporters (EAATs) are expressed in astrocytes, oligodendrocytes, and neurons.
There are five members of the EAAT family. Those expressed in astrocytes and
oligodendrocytes are named EAAT1 and EAAT2 in humans, and respectively known as
GLAST and GLT-1 in rats and mice (Pines et al., 1992; Rothstein et al., 1992; Storck et al.,
1992; Chaudhry et al., 1995; Dehnes et al., 1998; Domercq and Matute, 1999; DeSilva et al.,
2009). The third member, EAAT3 or EAAC1, is the main glutamate transporter seen in
neurons (Rothstein et al., 1994; Conti et al., 1998; Danbolt et al., 1998; Holmseth et al.,
2012). The final two, EAAT4 and EAAT5 are found in Purkinje cells and the retina,
respectively (Arriza et al., 1994; Rauen et al., 1996; Bar-Peled et al., 1997; Furuta et al.,
1997; Dehnes et al., 1998; Pow and Barnett, 2000). Interestingly, GLT-1 and GLAST are
responsible for transporting 90% of the extracellular glutamate out of the synapse
(Rothstein et al, 1996).

Therefore the next sections will elaborate on the function,

localization and regulation of these astrocytic glutamate transporters.
21

Figure

1.4.

EAAT1/GLAST

and

EAAT2/GLT1-mediated

glutamate

transport

mechanism. (A) EAAT1/GLAST and EAAT2/GLT-1 are made up of 8 transmembrane
domains and function as homotrimers. (B) Two sodium ions and one hydrogen ion bind to
the extracellular face of the transporter. (C) Glutamate loosely binds. (D) A third sodium
ion binds stabilizing the glutamate binding and closes the conformation of the transporter.
(E and F) Another conformational change occurs and the glutamate and ions are
internalized and released into the cell. (G) Potassium binds on the intracellular side and is
transported out into the extracellular space.
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Mechanism of glutamate transport
EAAT1/GLAST and EAAT2/GLT-1 are both 8-transmembrane domain proteins (Figure
1.4A) that form functional homotrimers and have not been shown to form heteromers
(Haugeto et al., 1996; Focke et al., 2013; Canul-Tec et al., 2017). They have similar affinities
for glutamate, with a range of reported Km values of 1-90μM depending on the
experimental design (Arriza et al., 1994; Wadiche et al., 1995; Danbolt, 2001; Bergles et al.,
2002; Mim et al., 2005). Measurements in slice culture tend to be around 20μM (Tzingounis
and Wadiche, 2007). Remarkably, these transporters are able to maintain an almost 106fold gradient between the extracellular and intracellular glutamate concentrations which
are within the nM and mM range, respectively (Zerangue and Kavanaugh, 1996;
Vandenberg and Ryan, 2013). Due to this fact, these transporters are coupled to a Na+/K+
ATPase to offset the energy cost necessary to transport glutamate against this enormous
concentration gradient.
EAAT1/GLAST and EAAT2/GLT1 work as antiporters that internalize a glutamate
molecule together with three sodium and one hydrogen ions and extrude one potassium
ion (Zerangue and Kavanaugh, 1996; Levy et al., 1998). Glutamate transport is initiated by
the binding of one hydrogen and two sodium ions at the reentrant loop between TMs 7 and
8 (Figure 1.4B). This event induces a conformational change in the substrate-binding site
that allows for an initially loose association with glutamate (Figure 1.4C) (Ewers et al.,
2013; Focke et al., 2013; Reyes et al., 2013). After glutamate binding, the third sodium ion
binds and another conformational change takes place closing the active site. The third
sodium ion binding and conformational change produce a considerably stronger
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connection with the glutamate guaranteeing its internalization as opposed to simply
binding to the transporter (Figure 1.4D) (Ewers et al., 2013; Reyes et al., 2013). The
glutamate molecule and the sodium and hydrogen ions are then translocated across the
membrane using a piston motion and released into the cell (Figure 1.4E and F) (Billups et
al., 1996; Zerangue and Kavanaugh, 1996; Levy et al., 1998; Reyes et al., 2009; Verdon et al.,
2014). The opening of the loop into the cell and dissociation of sodium, hydrogen, and
glutamate reveals a binding site for potassium, which is then transported across the
membrane and released into the extracellular space (Figure 1.4G). The binding and
transport of potassium is assumed to be the rate limiting step although the outward
transport mechanism remains poorly understood (Georgieva et al., 2013; Hänelt et al.,
2013).
As discussed in the following section, while EAAT1/GLAST and EAAT2/GLT1 function
similarly, their differential localization and developmental expression suggest that each of
these transporters play specific roles and are subjected to different regulatory mechanisms.

Differential developmental expression and brain localization of EAAT1/GLAST and
EAAT2/GLT-1
During brain development, GLAST is present in radial glia cells. Interestingly, in addition
to being expressed in astrocytes in the adult brain, GLAST expression remains present in
the adult stem cells in the SVZ (Kriegstein and Alvarez-Buylla, 2011). Unlike GLAST, GLT-1
protein cannot be detected in astrocytes until well into postnatal development (Figure 1.5)
(Bar-Peled et al., 1997; Furuta et al., 1997).
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Figure 1.5. Developmental expression of GLAST and GLT-1. GLAST expression is
already quantifiable early in embryonic development around E9 or E10 days due to its
expression in radial glia cells. In contrast, GLT-1 expression cannot be seen until the second
week of postnatal development.
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However, as the main transporter in the adult brain, GLT-1 expression is observed
throughout the grey and white matter and is highest in the forebrain (Shibata et al, 1996;
Yamada, et al 1998).

Astrocytes in the cortex and the cerebellum express both

transporters, however with differing ratios of expression depending on the brain region
(Lehre et al., 1995). In contrast to many other areas of the brain, in the hippocampus, GLT1 and GLAST are detected in morphologically distinct astrocytes isolated from this region.
GLAST expression was enriched in flat GFAP positive polygonal cells whereas GLT-1 was
expressed in highly arborized astrocytes that are indicative of a more differentiated cell
(Shibata et al., 1997; Perego et al., 2000; Schreiner et al., 2014).
Interestingly, GLAST expression seems to be dependent on the spatial localization of the
astrocyte. Astrocytes facing the pia mater or those adjacent to capillaries express far less
GLAST than the membranes surrounding glutamatergic synapses (Chaudhry et al., 1995).
In addition to moderate expression throughout the rest of the CNS, GLAST is the main
transporter in circumventricular organs (Berger and Hediger, 2000), the inner ear
(Glowatzki et al., 2006) and the cerebellum (Lehre and Danbolt, 1998). Additional cell
types that express GLAST are the nuclei of gliomas (Ye et al., 1999), microglia (Kondo et al.,
1995) and oligodendrocytes (Kondo et al., 1995; Domercq and Matute, 1999; MartinezLozada et al., 2014). Importantly astrocytic glutamate transporters may also play a crucial
role controlling glutamate levels even before the establishment of functional synapses, a
problem that will be the center of the following section.

Glutamate in development
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It is important to stress that the regulation of local glutamate concentrations is not only
important from the point of view of synaptic transmission. Multiple lines of evidence
indicate that glutamate is also a signaling molecule playing critical functions during brain
development, participating in processes that control cell proliferation, dendritic growth,
and migration, all crucial events for correct CNS maturation. Glutamate has been shown to
promote the proliferation of NPCs through activation of NMDA and AMPA receptors on
neuronal progenitors (Luk et al., 2003; Luk and Sadikot, 2004; Brazel et al., 2005).
Furthermore, Demarque et al. found that unstimulated “silent” neurons in the hippocampus
exhibited a slow current during a specific window early in development indicating that
even without an action potential these neurons were activated.

This current was

completely blocked by combined inhibition of GABAA and NMDA receptors, and was
prolonged by inhibition of glutamate transporters suggesting that GABA and glutamate
were already present in the extracellular space as opposed to having been exocytosed upon
stimulation. It was confirmed that this mechanism of GABA and glutamate release was
neither calcium or SNARE-mediated suggesting both the existence of a basal level of
glutamate in the extracellular space and a non-action potential generating paracrine
function for glutamate in development (Demarque et al., 2002). Manent et al., showed that
this non-canonical release of glutamate and subsequent basal signaling mediated neuronal
precursor migration (Manent et al., 2005; Manent, 2006; Manent and Represa, 2007).
Interestingly, Behar et al., showed that while blocking NMDA receptors decreased the rate
of migration, over activation of these receptors induced migratory defects, further
emphasizing the necessity of tight regulation of glutamate levels (Komuro and Rakic, 1993;
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Behar et al., 1999). Additionally, Kwon and Sabatini showed that de novo dendritic spine
growth could be induced by glutamate. The growth was inhibited by both the addition of
extracellular magnesium and the depletion of calcium stores indicating that this effect was
dependent on NMDA receptor activation (Kwon and Sabatini, 2011). From these functions
it is clear why extracellular glutamate concentrations must be so tightly controlled along
CNS development. As detailed in the next section, the astrocytic glutamate transporters
also play a crucial role in this regulation.

GLT-1 and GLAST in development
As discussed above, it is now well known that glutamate plays an important role in the
correct development of the CNS by influencing a variety of crucial events that showcase the
necessity of tight regulation of glutamate levels. The roles of the glutamate transporters
GLT-1 and GLAST in development have been studied by a number of ways including the use
of germ line knockout, antisense knockdown, and uptake inhibitors (Rothstein et al., 1994;
Tanaka et al., 1997; Watase et al., 1998; Matsugami et al., 2006). Interestingly, while many
in vitro experiments have shown how glutamate can influence proliferation, differentiation
and migration in developmental paradigms, in vivo genetic manipulation of neuronal
glutamatergic signaling components like the NMDA (Kutsuwada et al., 1996; Messersmith
et al., 1997), AMPA and kainate receptors (Zamanillo et al., 1999; Meng et al., 2003), and
vesicular glutamate transporters, VGLUT1 and 2 (Fremeau, 2004; Wojcik et al., 2004),
showed no gross malformation of the brain.

It is hypothesized that other

neurotransmitters, like GABA, which is excitatory in the early postnatal brain, can
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compensate for the loss of glutamate signaling (Ben-Ari et al., 1989; Ben-Ari, 2002; Represa
and Ben-Ari, 2005).
In contrast, while developmentally normal, about 50% of GLT-1 -/- KO mice experience
lethal seizures around 3 weeks of age, and exhibit an increased risk of acute cortical injury.
Furthermore, heterozygous (+/-) GLT-1 KO mice show a milder non-lethal phenotype that
is marked by hyperlocomotion, sensorimotor impairment, and altered fear conditioning
suggesting a role for GLT-1 in the more developed brain (Tanaka et al., 1997; Kiryk et al.,
2008). A GLAST -/- mouse, while not as severe as its GLT-1 -/- counterpart, has significant
motor discoordination and is prone to cerebellar injury as GLAST is the main transporter in
the cerebellum in the adult brain. While there were no anatomical changes, GLAST -/- do
show an increase in swelling as a result of traumatic brain injury (Watase et al, 1998).
Although the single KO mice indicate a role for these transporters in injury, the double
KO animals illustrate the necessity of glutamate transporters in development. A GLAST -/and GLT-1 -/- double KO is embryonic lethal and shows a number of major developmental
flaws in gross brain structure. Overall, a number of architectural malformations occurred
including enlarged ventricles, alterations to the pallial-subpallial boundary, and unclear
division of the cortical plate and the intermediate zone of the cortex. These malformations
alone add sufficient evidence indicating that glutamate regulation is necessary for the
correct formation of the brain. In addition, migration and differentiation are affected as
evidenced by a missing layer in the olfactory bulb and the absence of pyramidal neurons in
the hippocampus. Other migratory defects were present at cortical plate neurons, showing
incorrect formation of the layers in the cortex. Furthermore, the decreased incorporation of
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BrdU in the ventricular zone suggests that the presence of GLT-1 and GLAST in the
embryonic brain is essential to the proliferation of cells in this area. Analysis of nestin
staining showed that these neurons failed to exit the VZ, and if they were successful, the
layers formed were significantly less dense. The greatest deficits in the double KO were
seen in locations where both transporters are expressed, supporting the critical
importance of these glutamate transporters in brain development.
However, the mechanisms that regulate the expression of these transporters is still not
completely understood. As indicated above, the findings presented in this thesis work show
that the expression of GLAST/EAAT1 in both rodent and human astrocytes is regulated by
nociceptin and its receptor, NOPR. Because NOPR is a member of the opioid receptor
family, the following sections will focus on this group of molecules that are known to
mediate multiple actions including effects in pain control (Reinscheid et al., 1995; Mogil et
al., 1996; King et al., 1997; Pan et al., 2000; Zeilhofer and Calo, 2003), reward (Marquez et
al., 2008; Koizumi et al., 2009), learning and memory (Mamiya et al., 1998; Noda et al.,
2000; Higgins et al., 2002; Hiramatsu et al., 2008; Kuzmin et al., 2009), addiction (Ueda et
al., 1997; Rizzi et al., 2000; Mamiya et al., 2001; Chung et al., 2006; Marquez et al., 2008,
2013; Sakoori and Murphy, 2009; Kallupi et al., 2013, 2017), and more recently,
inflammation (Buzas et al., 1999, 2002; Rosenberger et al., 2001; Buzas, 2002; Depner et al.,
2003; Fu et al., 2007; Carvalho et al., 2008; Gavioli and Romão, 2011; Gavioli et al., 2015)
and CNS development (Zaveri et al., 2006; Eschenroeder et al., 2012; Meyer et al., 2017).

Nociceptin and the opioid family
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The opioid receptor family
Opium-derived painkillers have been in use for centuries and the existence of specific
receptors was postulated as early as the 1950s and 60s; however, evidence for the
presence of opioid-specific receptors in the brain was not presented until the early 1970’s.
These receptors were first characterized during an investigation into the binding locations
of radiolabeled versions of the most commonly used pain management medications like
morphine, etorphine, methadone, and naloxone (Pert and Snyder, 1973; Simon et al., 1973;
Terenius, 1973). The unique responses elicited by certain combinations of these drugs led
to the hypothesis that three separate opioid receptors were present in the brain, now
known as the classical opioid receptors. The receptor that bound morphine, the most
commonly used painkiller at the time, was called the μ-opioid receptor (MOR). The
receptor that responded to ketacyclazocine was named the κ-opioid receptor (KOR)
(Martin et al., 1976). The final classical opioid receptor to be discovered was named the δopioid receptor (DOR) as it was found in the rat vas deferens (Lord et al., 1977). Almost 20
years later, multiple labs used the then recently cloned cDNA of the classical opioid
receptors as a probe, and a 4th opioid receptor was discovered and named opioid receptor
like-1, to be later renamed the nociceptin receptor or NOPR (Bunzow et al., 1994; Fukuda
et al., 1994; Mollereau et al., 1994; Wang et al., 1994). Cloning of MOR, KOR and DOR,
uncovered a remarkable amino acid similarity, 60-70%, with the highest resemblance
being in the seven transmembrane (TM) domains and the intracellular G-protein binding
loops (Figure 1.6) (Chen et al., 1993a; b; Fukuda et al., 1993; Li et al., 1993; Meng et al.,
1993; Nishi et al., 1993; Yasuda et al., 1993; Abood et al., 1994).
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Figure 1.6. The Nociceptin receptor shares significant sequence homology with the
classical opioid receptors. (A) NOPR is a 7-transmembrane domain GPCR with high
similarity to the classical (μ-,δ-, and κ-) opioid receptors. Residues in red are identical
among all of the receptors. Yellow residues are shared by NOPR, MOR and DOR. Purple
residues are common to both NOPR and KOR. Royal blue residues are found in both DOR
and NOPR. Orange residues are seen in both MOR and NOPR. Greens are shared by MOR,
KOR and NOPR. Finally, aqua residues are seen in NOPR, DOR and KOR. (B) The similarity
in amino acid sequence is highest, between 50 and 80%, in the transmembrane domains
and the intracellular loops. The lowest similarity is in the extracellular loops, 10-35%,
which are responsible for the specificity of binding selective ligands.
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A

B
MOR

DOR

KOR

Transmembrane Domains
TM1

14/26 (54%)

14/26 (54%)

11/26 (42%)

TM2

15/22 (69%)

16/22 (72%)

16/22 (72%)

TM3

17/22 (77%)

17/22 (77%)

18/22 (81%)

TM4

11/23 (48%)

13/23 (57%)

8/23 (35%)

TM5

14/25 (56%)

14/25 (56%)

14/25 (56%)

TM6

13/21 (62%)

12/21 (57%)

15/21 (71%)

TM7
Intracellular Loops
IL1

14/22 (64%)

16/22 (72%)

16/22 (72%)

9/13 (69%)

8/13 (62%)

9/13 (69%)

IL2

11/19 (58%)

11/19 (58%)

11/19 (58%)

IL3
Extracellular Loops
EL1

21/28 (75%)

20/28 (72%)

23/28 (82%)

5/15 (33%)

7/15 (46%)

8/15 (53%)

EL2

5/23 (22%)

4/23 (17%)

8/23 (34%)

EL3

2/15 (13%)

3/15 (20%)

2/15 (13%)
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These structural (Figure 1.6) and functional similarities were also subsequently confirmed
for NOPR (Mollereau et al., 1994). Previous evidence indicated that the opioid receptors
were part of the G-protein coupled receptor superfamily (GPCR) and based on their
sensitivity to pertussis toxin, they were later classified as members of the Gαi/o group of
GPCRs (Burns et al., 1983). All four opioid receptors exhibit the capacity to decrease the
production of cyclic adenosine monophosphate (cAMP) through a classical response in
which ligand-dependent activation results in Gi subunit dissociation and subsequent
inhibition of adenylyl cyclase (Konkoy and Childers, 1989; Evans et al., 1992; Chen et al.,
1993a; Meng et al., 1993; Wang et al., 1993; Yasuda et al., 1993). Opioid receptor signaling
is also known to control the activity of potassium and calcium channels. Dissociation of Gαi
from Gβγ, and interaction of the Gα subunit with KIR3, activates these inward rectifying
potassium channels (Williams et al., 1982; Torrecilla et al., 2002; Torrecilla and Quillinan,
2008). Activation of the different opioid receptors causes a decrease of calcium currents
mediated by P/Q-type, N-type, and L-type calcium channels. This inhibitory effect that
appears to result from direct inhibitory binding of the Gβγ subunit to the calcium channels
(Bourinet et al., 1996; Zamponi and Snutcht, 1996; Rusin et al., 1997). These effects result
in changes in the net ionic balance and activation of a number of different second
messenger systems such as those mediated by calcium, phosphatidylinositols, arachidonic
acid and diacylglycerols (Macdonald and Werz, 1986; Gross and Macdonald, 1987; North et
al., 1987; Surprenant et al., 1990; Tatsumi et al., 1990; Schroeder et al., 1991; Seward et al.,
1991; Wimpey and Chavkin, 1991; Vaughan et al., 1997).
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Table 1. The opioid receptor family members and their affinity for different
molecules. The table shows the Ki values (nM) of different molecules for each of the 4
opioid receptors. Nociceptin selectively binds to NOPR with almost 1000-fold greater
affinity than to any of the other opioid receptors. NOPR shows significantly lower affinity
for endogenous opioids as compared to classical opioid receptors. A.(Merg et al., 2006);
B.(Raynor et al., 1994); C.(Yasuda et al., 1993); D.(Lapalu et al., 1998); E.(Butour et al.,
1997); F.(Nishi et al., 1993); G.(Meng et al., 1993); H.(Fukuda et al., 1993); I. (Zaveri et al.,
2001); J.(Chen et al., 1993a); K.(Chen et al., 1993b); L.(Khroyan et al., 2009); M. (Mollereau
et al., 1994).
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MOR

KOR

DOR

NOPR

Prodynorphin
Dynorphin A (1-8)
Dynorphin A (1-17)
Dynorphin B (1-13)

22.3A
21.4A
13A

0.275A
0.082A
3.8A

32.6A
111.9A
12.8A

>1000A
168.1A
860A

Proenkephalin
[met]Enkephalin
[leu]Enkephalin

0.65B
3.4B

>1000C
>1000C

1.7B
4B

>1000D
>1000D

Proopiomelanocortin
b-Endorphin
1B

52B

1B

192

Prepronociceptin
Nociceptin

>1000

104D

>1000

0.17E

Other ligands
Morphine
Buprenorphine
Naloxone

1.8F
1.5I,L
1.7-3.7J

94G
0.8I
20K

>1000H
4.5I
95H

>1000L
112I
>1000M
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As later discussed, the studies in this thesis work indicated that activation of NOPR in
astrocytes results in downstream activation of a PI-3K/Akt signaling pathway that
mediates a nociceptin-dependent stimulation of GLAST expression.

Opioid peptides
The idea of an endogenous ligand that can alleviate pain predates the discovery of the
opioid receptor proteins. Mayer et al, found that treatment with nalorphine, a compound
that negates the effects of morphine, reversed the pain relief produced by electrical
stimulation suggesting the existence of some endogenous anti-nociceptive molecule
released by the stimulation (Mayer et al., 1971). Interestingly, nociceptin, the endogenous
ligand of NOPR, was the first receptor ligand elucidated using a technique known as
“reverse pharmacology”. In classical pharmacology, a natural or synthetic molecule is found
to elicit the desired effect and then the biological target (i.e. a receptor) of that ligand is
identified. In contrast, reverse pharmacology uses the biological target, in this particular
case the nociceptin receptor, as a probe to find molecules with binding affinity, which are
then assessed for function.

In the case of the NOPR, Chinese hamster ovary (CHO) cells

stably expressing this receptor (known at that time as ORL-1) were treated with
fractionated extracts from either rat brain or porcine pituitary gland. The concentration of
cAMP was monitored as a reporter of ligand binding and receptor activity. This technique
led to the discovery of a 17-amino acid peptide that had the capacity to potently inhibit
cAMP formation in vitro and was capable of inducing hyperalgesia when given
intracerebroventricularly (i.c.v) (Meunier et al., 1995; Reinscheid et al., 1995). Because the
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first identified physiological role for this peptide was causing pain, or nociception, this
molecule was named nociceptin (Meunier et al., 1995).
The endogenous ligands of the classical opioid receptors were discovered in the mid1970s. The enkephalin family of opioid peptides was characterized as two five-amino acid
peptides differing only in their terminal amino acid. [Met]Enkephalin and [Leu]Enkephalin
activate both MOR and DOR (Hughes, 1975; Hughes et al., 1975). Next, a 31 amino acid
peptide, termed β-endorphin, was isolated from human and camel pituitary gland and was
shown to be selective for MOR (Li and Chung, 1976; Li et al., 1976a; b; Loh et al., 1976).
Finally, the KOR selective ligand, dynorphin, was discovered (Goldstein et al., 1979).
It was later found that all of the endogenous opioid ligands are cleavage products of
larger peptide precursors, proenkephalin (PENK), proopiomelanocortin (POMC),
prodynorphin (PDYN), and prepronociceptin (PPN) (Chang et al., 1980; Comb et al., 1982;
Gubler et al., 1982; Kakidani et al, 1982; Noda et al., 1982; Meunier et al., 1995).
Interestingly, there is some cross over in the binding of classical opioids and ligands, for
example, [Met]Enkephalin binds to both MOR and DOR (Table 1). However, despite the
sequence and structural similarity, NOPR shows no affinity for any of the endogenous
opioids and nociceptin shows no appreciable binding to any of the other members of the
opioid receptor family (Bunzow et al., 1994; Butour et al., 1997; Meunier et al., 2000).
Furthermore, the temporal expression of each of these receptors and peptides is unique.
During development β-endorphin, enkephalin, and dynorphin A, are quantifiable as early as
embryonic day 11.5 (E11.5).

Levels of the latter two peptides continue to increase

throughout embryonic and early postnatal development, however, β-endorphin decreases
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to background amounts by postnatal day 1 (PD1) until around 6 days postnatal where
expression increases until adult levels are reached around PD30 (Bayon et al., 1979; Rosen
and Polakiewicz, 1989; Rius et al., 1991). In sharp contrast to the classical opioid peptides,
the expression of nociceptin was shown to be higher in embryonic and early postnatal
development than in the adult brain (Saito et al., 1995, 1997; Ikeda et al., 1998; Meyer et al.,
2017).

Interestingly, MOR, KOR, and NOPR can all be detected during embryonic

development, but DOR expression is not observed until postnatal brain maturation (Barg
and Simantov, 1991; Rius et al., 1991; Neal et al., 2001).

The opioid systems in synaptic transmission
Opioids and specifically the nociceptin system have been well studied for their role in
the modulation of synaptic transmission. Nociceptin and NOPR were shown to induce
potent effects on neurotransmission both pre- and postsynaptically. Kallupi et al., showed
that treatment of brain slices with nociceptin caused a decrease in the frequency and
amplitude of miniature excitatory postsynaptic currents (mESPCs) in the central amygdala,
a major center for processing and relaying pain information. The decreased frequency
indicates that nociceptin had an effect presynaptically, suggesting that activation of NOPR
on presynaptic neurons prevents neurotransmitter release (Kallupi et al., 2013). This effect
is due to NOPR’s Gαi/o modulation of neurotransmitter release.

Vesicular fusion is

mediated by intracellular calcium concentrations and as mentioned previously, activation
of Gαi/o closes calcium channels preventing fusion and therefore neurotransmission.
Furthermore, Yu et. al., found that nociceptin treatment decreased the amplitude of the
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mEPSCs in Cornu Ammonis Layer 1 (CA1) and

the dentate gyrus, suggesting that

nociceptin is exerting an effect postsynaptically, this could be a direct effect of nociceptin
on the postsynaptic receptors or an indirect effect causing changes in receptor density,
activation or downstream signaling (Yu et al., 1997; Yu and Xie, 1998). These studies also
postulated that the dampening effect of nociceptin on postsynaptic NMDA receptors may
indicate a role in long term potentiation (LTP) (Yu and Xie, 1998). This hypothesis was
later supported by a number of studies showing that both NOPR -/- and prepronociceptin /- mice exhibit increased LTP and spatial awareness (Mamiya et al., 1998; Higgins et al.,
2002; Kuzmin et al., 2004, 2009). The inhibitory effect of nociceptin has been seen in the
thalamus, the lateral amygdala, the substantia nigra, suprachiasmatic nucleus, and the
dorsal horn of the spinal cord (Yu and Xie, 1998; Ahmadi et al., 2001; Meis and Pape, 2001;
Marti et al., 2002; Meis et al., 2002; Gompf et al., 2005).
Furthermore, MOR, DOR and KOR activation also exhibits an inhibitory effect on synaptic
transmission (Wagner et al., 1993; Acosta and López, 1999; Emmerson and Miller, 1999;
Terman et al., 2000). Treatment of in situ rat brains with DAMGO, a MOR agonist, showed a
decrease in the amplitude of evoked EPSCs in the central amygdala suggesting a
postsynaptic mechanism of modulation (Zhu and Pan, 2004).

In addition to this

postsynaptic effect and similarly to nociceptin/NOPR, a change in the frequency of mESPCs
was also seen after treatment with DAMGO suggesting a presynaptic mechanism as well
(Zhu and Pan, 2005). The modulation of synaptic transmission, specifically the dampening
of glutamatergic transmission makes this family of receptors and ligands an interesting
target for modulating excitability in the brain.
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Functions of endogenous opioids in brain development
As detailed above the unique patterns of embryonic and early postnatal expression of
both peptide ligands and members of the opioid receptor family (Bayon et al., 1979;
Kornblum et al., 1987; Petrillo et al., 1987; Rosen and Polakiewicz, 1989; Rius et al., 1991;
Saito et al., 1995, 1997; Ikeda et al., 1998; Zhu et al., 1998; Meyer et al., 2017), suggested
the existence of critical functions during brain development. Several lines of investigation
indeed implicated the opioid system in a number of developmental events including cell
proliferation, differentiation, neurite outgrowth, and neuronal migration.
The first studies into the role of opioid receptors in a developmental paradigm used
naltrexone, a pan-opioid receptor antagonist. Hauser, et al. showed that the cerebral cortex
and basilar hippocampus of newborn rats given daily injections of naltrexone (50 mg/kg),
possessed dendrites that exhibited significant increases in both length and number of
spines (Hauser et al., 1987). Interestingly, animals injected with a lower daily dose of
naltrexone, 1 mg/kg, a dose only able to inhibit receptors 10-12 hr/day, displayed the
opposite response and had decreased spines indicating a positive effect of low dose opioids
(Zagon and McLaughlin, 1991). These finding emphasized that a careful balance of opioid
receptor activation is crucial to correct brain development.
Opioids were also shown to have important effects on glial cells. Studies in which
astrocytes were exposed to DOR agonists demonstrated decreased DNA synthesis and cell
numbers. Conversely, treatment of astrocytes with naltrexone alone showed an increase in
DNA synthesis indicating that endogenous opioids play a role in astrocyte development
(Hauser and Stiene-Martin, 1991; Stiene-Martin and Hauser, 1991; Hauser et al., 1993;
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Gurwell et al., 1996; Stiene-Martin et al., 2001). In contrast to astrocytes, immature
oligodendrocytes, upregulate DNA synthesis after exposure to a KOR agonist, and lack of
KOR in Jimpy mice is accompanied by lack of myelin and oligodendrocyte death (Knapp
and Hauser, 1996; Knapp et al., 1998; Stiene-Martin et al., 2001). In addition, previous
results from our laboratory showed that in vivo exposure to methadone and
buprenorphine, two opioid analogues used for the treatment of pregnant opioid addicts,
results in altered timing of oligodendrocyte maturation and rat brain myelination (Sanchez
et al., 2008; Vestal-Laborde et al., 2014). Altogether, these findings strongly support a role
for the endogenous opioid system in glial development and function.
The nociceptin system represents an interesting target for neurodevelopmental studies
because of the significantly higher nociceptin expression that occurs in embryonic and
early postnatal development, a critical period that includes neurite outgrowth, astrocyte
differentiation and synaptogenesis (Saito et al., 1995; Ikeda et al., 1998; Neal et al., 2001).
While relatively little is known about nociceptin in development, early studies with
cultured cells showed that the expression of the nociceptin precursor, prepronociceptin, is
transiently upregulated during neuronal differentiation and correlates with the appearance
of dendrites (Saito et al., 1995). Further research indicated that overexpression of
prepronociceptin, treatment of neurons with factors that upregulate prepronociceptin
mRNA or incubation with exogenously added nociceptin all showed an increase in neurite
outgrowth (Saito et al., 1995, 1996, 1997; Sirianni et al., 1999; Zaveri et al., 2006). These
were the first indications that nociceptin could play a role in brain maturation. More
recently, our lab showed that activation of NOPR by buprenorphine can affect the timing of
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oligodendrocyte differentiation and therefore myelination, a key developmental event
(Eschenroeder et al., 2012).
The results presented in this thesis indicate that both nociceptin and its receptor NOPR
are expressed in astrocytes in a developmentally regulated manner. Moreover, we found
that the nociceptin system has the capacity of controlling the expression of the astrocytic
glutamate transporter GLAST in both developing rat and human astrocytes. These findings
suggest that the nociceptin system plays a conserved critical function regulating glutamate
homeostasis in the developing brain (Meyer et al., 2017)
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CHAPTER 2
MATERIALS AND METHODS
Materials
Sprague-Dawley rats were obtained from Harlan (Indianapolis, IN) and Charles River
(Wilmington, MA) Laboratories. LY294002 (2-Morpholin-4-yl-8-phenylchromen-4-one),
rabbit anti-pAKT, rabbit anti-EAAT1/GLAST and anti-EAAT2/GLT-1 antibodies, were all
obtained from Cell Signaling Technology (Danvers, MA). Nociceptin and BAN-ORL 24 ((2R)1-(phenylmethyl)-N-[3-(spiro[isobenzofuran-1(3H),4’-piperdin]-1-yl)propyl-2pyrrolidinecarboxamide), were purchased from Tocris Bioscience (Ellisville, MO).
Rapamycin was a generous gift from the lab of Dr. Sarah Spiegel. JAK inhibitor I (2-(1,1Dimethylethyl)-9-fluoro-3,6-dihydro-7H-benz[h]-imidaz[4,5-f]isoquinolin-7-one)

was

purchased from EMD Millipore (Temecula, CA). Chicken anti-GFAP, rabbit anti-nociceptin,
TFB-TBOA

((3S)-3-[[3-[[4-(Trifluoromethyl)benzoyl]amino]phenyl]methoxy]-L-aspartic

acid), and Super Signal West Dura chemiluminescence reagent were obtained from
ThermoFisher Scientific (Rockford, IL). Guinea pig anti-nociceptin and rabbit anti-NOPR
antibodies were from Neuromics, Inc. (Edina, MN). Rabbit anti-GFAP and mouse anti-actin
antibodies were obtained from Sigma-Aldrich (St. Louis, MO). Anti-ALDH1L1 antibody was
from Novus Biologicals (Littleton CO). Dulbecco’s Modified Eagle Medium/Ham’s F12
(DMEM-F12), Dulbecco’s Modified Eagle Medium (DMEM), N2 supplement, anti-rabbit
AlexaFluor®488, anti-chicken AlexaFluor® 594 and the Tyramide Signaling Kit were
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purchased from Life Technologies (Frederick, MD). Digoxigenin-labeled probes for in situ
hybridization were obtained from Integrated DNA Technologies (Skokie, Il). All
electrophoresis supplies were from Bio-Rad laboratories (Hercules, CA). L-[3,4-3H]aspartic acid (12.9 Ci/mmol) was obtained from Perkin Elmer (Waltham, MA). Except for
the horseradish peroxidase (HRP)-conjugated anti-guinea pig antibody (Life Technologies),
all HRP-labeled secondary antibodies and the anti-digoxigenin antibody were purchased
from Jackson ImmunoResearch (West Grove, PA).

Human and rat astrocyte cultures
Human cortical astrocytes prepared from fetal brain tissue provided by Advanced
Bioscience Resources (Rockville, MD) were cultured as previously described (Kordula et al.,
1998). All animal use and isolation of astrocytes were conducted in accordance with the
National Institutes of Health (NIH) recommendations and approved by the Virginia
Commonwealth University Animal Care and Use Committee (IACUC). Astrocyte cultures
were prepared from postnatal day 3 (PD3) Sprague Dawley rat pups according to a
modification of the method of McCarthy and DeVellis (McCarthy and de Vellis, 1980) as
follows. After decapitation, the cerebral hemispheres were rapidly dissected out, and the
meninges removed. The tissue was then finely minced (~2mm pieces) and forced through
two consecutive nylon meshes of 118μm and 75μm, respectively. The filtrate was collected
and spun at 1000xg for 5 min. The pellet obtained from 1/2 brain was resuspended in
DMEM-F12 containing 10% fetal bovine serum (FBS), penicillin (100IU/mL), and
streptomycin (100μg/mL) and placed in a 75cm2 culture flask. The flasks were maintained
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for 5 days at 37°C under 5% CO2, with medium replacement after three days. On the 6th
day, the flasks were shaken at 300rpm for 2 hrs to remove non-astroglial cells, followed by
passage of the attached astrocytes into 75cm2 flasks. The cells were maintained for 5-7
more days with the medium being replaced every 2 days. After reaching 80% confluence,
astrocytes were passed into 8-well glass chamber slides or 24-well plates and the medium
changed every 2 days until use. Neuronal, microglial and oligodendroglia contamination of
these cultures, as assessed by immunocytochemistry, was less than 5%.

Cell culture treatments with nociceptin, NOPR inhibitor, and kinase inhibitors
All cell culture treatments were carried out in FBS-free chemically defined medium (CDM)
[DMEM-F12 supplemented with N2 medium (50μg/mL transferrin, 5μg/mL insulin, 20nM
progesterone, 100μM putrescine, 30nM sodium selenite)].

For studies of nociceptin

effects, astrocytes were incubated for 24 hrs in CDM alone (controls), or CDM
supplemented with 1μM nociceptin, 100nM NOPR inhibitor BAN-ORL24 (NOPR-I) or a
combination of the two. For kinase inhibitor experiments, cells were treated with 1μM
nociceptin,

and

one

of

the

following

kinase

inhibitors:

30μM

LY2940002

[Phosphatidylinositol-3-Kinase (PI-3K) inhibitor], 1μM JAK Inhibitor I [Janus Kinase (JAK)
inhibitor], 25nM rapamycin [mammalian target of rapamycin (mTOR) inhibitor] 50μM
PD98059 [ERK (extracellular-signal related kinase (ERK)1/2 inhibitor], 10μM SB202190
[p38 mitogen activated protein kinase (MAPK) inhibitor], 30μM KN93 [Ca2+/calmodulindependent protein kinase II (CamKII) inhibitor], 10μM KT5720 [protein kinase A (PKA)
inhibitor], 10μM SQ22536 (adenylyl cyclase inhibitor), 100nM Go6983 [protein kinase C
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(PKC) inhibitor] or a combination of nociceptin and the kinase inhibitor.

For the short-

term signaling experiments, cells were preincubated for 15min in the presence or absence
of the appropriate kinase inhibitors.

In vivo administration of NOPR inhibitor
Sprague-Dawley rats were injected intraperitoneally with BAN-ORL24 in PBS at a dose of
1mg/kg/day on 3 different timelines as indicated in Figure 8. Pups were administered the
NOPR inhibitor from PD3 to PD9 (Group 1), PD3 to PD14 (Group 2), or PD9 to PD14 (Group
3). All controls were similarly injected with vehicle alone. At the end of the respective time
periods, the rats were anesthetized with isofluorane and sacrificed. The brains were
harvested, flash frozen on dry ice and kept at -80°C until use.

Immunoblotting
Western blot analyses were done as described previously (Eschenroeder et al., 2012).
After solubilization in the appropriate volume of Laemmli buffer (60 mM Tris–HCl buffer,
pH 6.8, containing 10% glycerol, 2% sodium dodecyl sulfate (SDS), and 5% 2mercaptoethanol), proteins from the cell cultures or tissue homogenates were separated by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) in 12% acrylamide and then
transferred to nitrocellulose for 1 hr at 100V. Non-specific binding was blocked with 3%
nonfat dry milk and 0.05% Tween-20 in PBS (blocking solution) for 1 hr at room
temperature. The membranes were then incubated overnight at 4°C with the appropriate
primary antibodies in blocking solution.
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The dilutions were as follows, anti-GFAP

(1:1,000), anti-EAAT1/GLAST (1:1,000), anti-EAAT2/GLT-1 (1:1,000), anti-actin (1:1,000),
anti-pAKT (1:2,000). After extensive rinsing in PBS, the membranes were re-blocked for 30
min and incubated for 2 hrs at room temperature in blocking solution with the appropriate
HRP-conjugated secondary antibody. Extensive rinsing in PBS was followed by detection of
immunoreactive bands using Super Signal West Dura Reagent.

The relative expression

levels of the immunoreactive bands were determined by scanning analysis of the X-ray
films using the N.I.H. ImageJ program, and the relative density values divided by β-actin
levels to correct for sample loading differences.

Determination of nociceptin concentrations by dot blot analysis
Nociceptin concentrations during postnatal brain development as well as nociceptin
secretion by cultured cells were both determined by dot blot analysis. For this, adequate
aliquots of total brain homogenates or astrocyte-conditioned culture media were pipetted
onto a nitrocellulose membrane using a 96-well Schliecher and Schuell Minifold vacuum
dot blot apparatus to generate even and uniform dots.

A parallel set of nociceptin

standards of known concentration was also included in the same membrane for
quantification of the samples. The membrane was dried for 2 hrs under vacuum before
being rehydrated in PBS and subsequently incubated for 1 hr in blocking solution (3%
nonfat dry milk and 0.05% Tween-20 in PBS). After overnight incubation with antinociceptin antibody (1:2,000) in blocking solution, the membrane was extensively washed,
subjected

to

incubation

with

HRP-conjugated

antibody

and

detection

by

chemiluminescence. Following scanning of the X-ray films, relative values were obtained by
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using the NIH ImageJ program and the concentration of nociceptin in the samples was
determined by extrapolation to the corresponding standard curve values.

Immunocytochemical analysis
For in vitro studies, cultured cells were fixed with 4% paraformaldehyde (PFA) for 20 min
at room temperature. For immunohistochemistry, rats were deeply anesthetized using a
2.5% solution of avertin and were then transcardially perfused with PBS followed by 4%
paraformaldehyde. Brains were then removed and cryopreserved in 30% sucrose
overnight before being flash frozen in OCT and cut into 30μm thick sections. Sections were
stored at 4°C until use. Fetal brain tissue samples from de-identified subjects, subjected to
number 4 IRB-exempt protocol, were obtained from the Department of Pathology at
Virginia Commonwealth University Medical Center. All in vivo tissue samples were subject
to epitope retrieval using incubation in 10mM sodium citrate for 30 min at 80°C and then
allowed to cool to room temperature. Following extensive rinses in PBS, non-specific
binding was blocked by incubation in PBS containing 5% normal goat serum and 0.3%
Triton® X-100 (blocking buffer) for 1 hr. Samples were incubated overnight at 4°C with the
appropriate primary antibody in blocking buffer. Antibodies were used at the following
dilutions: anti-GFAP (1:160), anti-EAAT1/GLAST (1:100), anti-NOPR (1:150), antinociceptin (1:250). In parallel, non-specific secondary antibody binding was assessed by
incubation of the tissue sections with the corresponding pre-immune serum in place of the
primary antibodies. After incubation, samples were rinsed with PBS, re-blocked for 30
min, and incubated for 2 hrs at room temperature in the presence of the appropriate
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secondary antibody. Nociceptin and NOPR were detected using a tyramide signal
amplification system (Life Technologies) according to the manufacturer’s instructions (See
Tyramide Signal Amplification for details). Cell cultures and tissue slides were mounted
with DAPI-containing Vectashield and visualized and imaged using one of the following
microscopes: Eppendorf Dissecting microscope, Zeiss Confocal LSM710 or Zeiss
AxioImager A1.

Tyramide signal amplification
TSA was used to visualize NOPR. This technique was used according to the manufacturer’s
recommendations and Wang et al., 1999 with minor modifications.

Briefly, the tissue

slices underwent epitope retrieval (incubation in 10mM sodium citrate at 80°C for 30 min).
After cooling to RT and successive rinses with PBS, endogenous peroxidase was quenched
using 3% H2O2 in PBS or 15 min. The tissue slices were then blocked in 5% NGS and 0.1%
Triton X-100 for 1 hr at RT and then incubated with anti-NOPR antibody (1:150) overnight
at 4°C. At this concentration, detection of anti-NOPR with the traditional fluorescently
conjugated secondary is below the threshold of detection. After 3x5min washes in PBS, the
slices were re-blocked for 20 min and subsequently incubated with an HRP-conjugated
anti-rabbit secondary antibody for 1.5 hrs at RT. After 3x5min rinses with PBS, tyramide
signal amplification was carried out for 15 min at RT. After 5x10 min additional washes
with PBS, the tissue was blocked for 15 min at RT and then incubated in rabbit antiALDH1L1 for 2 hrs at RT. This was followed by 3x5min PBS rinses, 15 min of blocking, and
then a 2 hr incubation with AlexaFluor 594-conjugated anti-rabbit secondary antibody.
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Due to the NOPR signal being below the threshold of detection of fluorescently conjugated
secondary antibody, no labeling of the NOPR by AlexaFluor 594-conjugated anti-rabbit
antibody was detectable. The appropriate anti-NOPR concentration was determined by
testing a range of antibody dilutions (1:10-1:500).

Fluorescent in situ hybridization for NOPR mRNA
In situ hybridization was performed by modification of a previously published protocol
(Wang et al., 2000). Cell cultures were fixed in 4% PFA for 20 min, rinsed with PBS and
stored at 4°C until use. Flash frozen tissue was cut into 10μm slices and stored at -80°C
until use when it was fixed in 4% PFA for 20 min and thoroughly rinsed in PBS. Cell
cultures and tissue sections were then rinsed once more with PBS and endogenous
peroxidase was quenched using 3% H2O2 in PBS for 20 min. After rinsing, samples were
acetylated (1.25% triethanolamine, 0.25% acetic anhydride in ddH2O) for 20 min at RT.
After further rinsing in PBS (3x5min), samples were permeabilized in 0.1% Triton X-100 in
PBS for 20 min. Tissues sections were re-fixed in 4% PFA for 20 min and rinsed 3 times in
PBS before proceeding with prehybridization. Samples were incubated in hybridization
buffer [50% Formamide, 5xSSC (1X SCC; 150 mM NaCl, 15 mM Na citrate), 10% dextran
sulfate, 500ug/mL salmon sperm DNA, 1% Triton X-100] for 1 hr at 37°C. A 50-mer
deoxyoligonucleotide probe for rat NOPR mRNA with the sequence 5’-CAG GGA TCT CCA
CCA GGC ACT CGA TCT CTT CAT CTT CCA CTT GTG CTG AA- 3’ or mouse/human NOPR
mRNA with the sequence 5’-GAT CTC CAC CAG GCA CTC GAT CTC TTC ATC CTC CAC TTG
TGC TGA GCC C-3’, both with a 3’ digoxigenin tag were synthesized and purified by IDT.
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These sequences correspond to the rat and mouse/human NOPR extracellular region
between transmembrane domains 4 and 5. Hybridization was done using 1ng/uL of
digoxigenin labeled-oligonucleotide probe in hybridization buffer for 37°C for 18h. After
hybridization samples were washed twice in 50% formamide/5xSSC at 37°C for 10 min,
then once in 2xSSC at 37° for 10 min, once in 2xSSC at RT for 10 min, 2x in 0.2xSSC at RT for
10 min and finally 3x in PBS at RT for 5 min.
The samples then underwent immunohistochemistry as previously described with
minor modifications (Meyer et al., 2017). The samples were blocked for 1 hr at RT in
blocking buffer (5% NGS and 0.1% Triton X-100 in PBS). A combination of mouse antidigoxigenin antibody (5 μg/ml) with anti-ALDH1L1 (1:1000) in blocking buffer was added
for 2 hr at RT. Cultures were rinsed in PBS 3x5 min. They were reblocked for 20 min
before the appropriate fluorescently conjugated secondaries were added for 2hr at RT.
Samples were then rinsed with PBS 4x5 min and mounted in Vectashield containing DAPI.

Image collection
Confocal Imaging was performed on a Zeiss LSM 710 confocal laser scanning microscope in
the Microscopy facility in the Department of Anatomy and Neurobiology at Virginia
Commonwealth University. Z-stacks of cortical sections spanning an optical thickness of
8μm (human samples) and 20μm (rat samples) were obtained using a 40X oil immersion
objective with a numerical aperture of 1.3. All images for each species were collected with
identical gain and offset using a pinhole of 1 Airy disc unit and an optical slice thickness of
0.42 μm (human samples) and 0.75 μm (rat samples). The X, Y, and Z dimensions of the
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collected images were 215.1296 μm by 215.1296 μm by 21 μm for rats and 215.1296 μm
by 215.1296 μm by 7.9836 μm for human samples. All confocal z-stacks are presented as a
single compressed image.

Aspartate uptake assay
The 3H-aspartate uptake assay was carried out using a modification of previously published
protocols (Matos et al., 2008; Escartin et al., 2011). After 24-hr incubation in CDM alone,
CDM with 1μM nociceptin, CDM with 100nM BAN-ORL24, or CDM with 100nM BAN-ORL24
and 1μM nociceptin, cells were pretreated for 10 min before the start of the uptake assay
with CDM alone, CDM with 300 mM DHK or CDM with 1μM TFB-TBOA. The different
groups of cells were then incubated in BSS-P (140mM NaCl, 5mM KCl, 1.2mM CaCl2, 1.2mM
MgSO4, 0.5mM KH2PO4, 5mM Glucose, 5mM PIPES, pH 7.2) containing 0.5μCi of 3H-aspartic
acid and 100 μM non-radioactive aspartic acid for different times at 37°C under 5% CO2. At
the end of the incubation, the culture plates were placed on ice and carefully rinsed three
times in ice-cold BSS-P. Cells were then lysed with 200μl 0.5N NaOH and aliquots used for
measurement of radioactivity by liquid scintillation counting and protein determination by
the Bradford assay (Bio-Rad).

NOPR knockout mice
The NOPR knockout (KO) mice were raised in the laboratory of Dr. Kabirullah Lutfy at
Western University of Health Sciences (Pomona, CA). Mice lacking NOPR (Nishi et al.,
1997) and their wild-type controls were originally obtained from Dr. Hiroshi Takeshima
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(Department of Biochemistry, Tohoku Graduate School of Medicine, Sendai, Miyagi 9808575, Japan). Male and female heterozygous mice were generated from mating of KO and
wild-type mice and fully backcrossed on a C57BL/6J mouse strain for 12 generations.
Heterozygous breeding pairs were then mated to generate mice lacking NOPR and their
wild-type controls. Mice were provided ad libitum access to water and food in a 12hr
light/dark cycle. Pups were genotyped employing a standard polymerase chain reaction
(PCR) protocol, using samples obtained from ear snips. All the experimental procedures
were conducted according to the NIH guidance and were approved by the IACUC at
Western University of Health Sciences.

Statistical analysis
For all conditions in cell culture, incubations were carried out in at least triplicate (3 to 6
wells/condition) and experiments were repeated a minimum of three times. Statistical
analysis was performed using the mean values from each experiment. The nonparametric
tests Mann-Whitney (for two group comparisons) or one-way analysis of variance on ranks
(Kruskal-Wallis test) were used when comparing more than two experimental groups. All
analyses were carried out using the GraphPad Prism program (La Jolla, CA). Differences
were considered statistically significant when P values were <0.05.

56

RESULTS

Postnatal rat brain maturation is accompanied by a progressive decrease in nociceptin
expression
Our previous findings suggested a role for nociceptin in oligodendrocyte maturation and
early myelination (Eschenroeder et al., 2012). Further support for the involvement of
nociceptin in brain development is the observation that mRNA levels encoding
prepronociceptin, the precursor of nociceptin, are higher in the immature than in the adult
rodent brain (Ikeda et al., 1998; Neal et al., 2001). Moreover, our analysis of nociceptin
protein levels in cerebral hemispheres from rat pups, revealed the highest expression
between postnatal days 2 and 5, with peak values of 797.2±34.3 and 936.0±113.5 fmol/μg
of protein, respectively (Fig. 1). However, the expression of this molecule gradually
decreases, reaching values at 21 days after birth that are about 6-fold lower than those
observed in the 5-day-old pups. Interestingly, the highest levels of postnatal nociceptin
expression overlap with the peak of astrocyte development that is observed in rodents
between 3 and 5 days of age (Mission et al., 1991), raising the possibility that the
nociceptin system may play a role in astrocyte maturation.

Nociceptin and NOPR expression in developing rodent and human astrocytes
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Figure 2.1. Postnatal brain maturation is accompanied by a progressive decrease in
nociceptin expression. Nociceptin expression was measured by dot blot analysis of total
brain homogenates prepared from rat pups at 2-, 5-, 9-, 13-, 18-, and 21- postnatal days.
Purified nociceptin was used to generate a standard curve as indicated under “Methods”.
The results, expressed as fmoles of nociceptin/μg of protein, are the average ± SEM from at
least 3 animals per age, PD5 vs. PD9 and PD13, **p<0.01; PD5 vs. PD18 and PD21,
***p<0.001
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Support for a role of nociceptin in developing astrocytes, was next provided by
immunocytochemical staining of rat brains at postnatal day 5 (PD5), a timing that
corresponds to the third trimester of CNS development in utero for humans (Fig. 2.2). In
these studies cortical astrocytes were identified by their labeling with both cytoplasmic
ALDH1L1 (Fig. 2.2-2.4 and 2.6-2.8) and cytoskeletal GFAP (Fig. 2.5 and 2.9). Co-staining
with ALDH1L1 and anti-nociceptin (Fig. 2.2, A-C) or anti-NOPR (Fig. 2.3, A-C) antibodies
clearly indicated the presence of nociceptin and NOPR in developing rat astrocytes.
Likewise, both components of the nociceptin system are present in immediate spatial
proximity with GFAP (Fig. 2.5). To further substantiate the presence of the nociceptin
system in astrocytes, we carried out in situ hybridization studies which demonstrated the
expression of NOPR mRNA in these cells (Fig. 2.4, A-C). Importantly, these findings are not
limited to rodents as localization of both components of the nociceptin system is also
observed in astrocytes of the human developing brain. Analysis of fetal brains at
gestational week 23, also showed the presence of both nociceptin and NOPR in human
cortical astrocytes identified by their labeling with ALDH1L1 (Fig. 2.6 and 2.7, A-C) and
GFAP (Fig. 2.8). Moreover, as in the rat brain, in situ hybridization studies clearly indicated
NOPR mRNA expression in astrocytes of the developing human brain (Fig. 2.9, A-C).

Interestingly, the expression of astrocytic NOPR appears to be developmentally
regulated. As shown in Figure 2.10 and 2.11, analysis of rat brain at different postnatal
ages (PD2-PD21) demonstrated the highest levels of astrocytic NOPR in the 2- and 5-dayold animals. However, analysis at older ages showed that NOPR expression subsequently
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Figure 2.2 In vivo expression of nociceptin developing rat astrocytes. Cortical brain
tissue slices from 9-day-old rats were subjected to immunohistochemistry using antiALDH1L1 (A), together with anti-nociceptin (B). (D-F) Non-specific labeling was assessed
by replacing the primary antibody with equivalent concentrations of pre-immune serum
from the respective host. Nuclei were counterstained with DAPI. Scale bar: 10μm. Rb
Serum: rabbit pre-immune serum control for rabbit anti-ALDH1L1, GP Serum: Guinea pig
pre-immune serum control for guinea pig anti-nociceptin.
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Figure 2.3 In vivo expression of NOPR in developing rat astrocytes. Cortical brain
tissue slices from 9-day-old rats were subjected to immunohistochemistry using antiALDH1L1 (A and D), together with anti-NOPR (B) antibody or their respective preimmune serum (E, G, and H). Nuclei were counterstained with DAPI. Scale bar: 10μm. Rb
Serum: rabbit pre-immune serum control for rabbit anti-ALDH1L1 and rabbit anti-NOPR.
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Figure 2.4 In vivo expression of NOPR mRNA in developing rat astrocytes. Cortical
brain slices were subjected to in situ hybridization using a digoxigenin-labeled probe for
NOPR mRNA (B) and immunohistochemical staining with anti-ALDH1L1 (A) antibody, as
indicated under "Methods". Notice the presence of NOPR mRNA in the ALDH1L1-labeled
astrocytes. Specificity for both the probe (D-F) and antibodies (G-I) was determined by
using a non-sense probe and pre-immune serum, respectively. Scale bar: 10μm. Rb Serum:
rabbit pre-immune serum control for rabbit anti-ALDH1L1, Ms Serum: mouse pre-immune
serum control for mouse anti-digoxigenin.
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Figure 2.5 In vivo expression of nociceptin and NOPR in developing rat astrocytes.
Cortical brain tissue slices from 5-day-old rats were subjected to immunohistochemistry
using anti-GFAP (A and D), together with anti-nociceptin (B) or anti-NOPR (E) antibodies.
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Figure 2.6. In vivo expression of nociceptin in developing human astrocytes. (A-F)
Gestational

week

23,

fetal

cortical

brain

tissue

slices

were

subjected

to

immunohistochemistry using anti-ALDH1L1 (A), together with anti-nociceptin (B). (D-F)
Non-specific labeling was assessed by replacing the primary antibody with equivalent
concentrations of pre-immune serum from the respective host. Nuclei were counterstained
with DAPI. Scale bar: 10μm. Rb Serum: rabbit pre-immune serum control for rabbit antiALDH1L1; GP Serum: guinea pig pre-immune serum control for guinea pig anti-nociceptin.
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Figure 2.7 In vivo expression of NOPR in developing human astrocytes. Gestational
week 23, fetal cortical brain tissue slices were subjected to immunohistochemistry using
anti-ALDH1L1 (A), together with anti-NOPR (B) antibody or respective pre-immune serum
(D and E). Nuclei were counterstained with DAPI. Scale bar: 10μm. Rb Serum: rabbit preimmune serum control for rabbit anti-ALDH1L1 and rabbit anti-NOPR.
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Figure 2.8 In vivo expression of NOPR mRNA in developing human astrocytes. Cortical
brain slices were also subjected to in situ hybridization using a digoxigenin-labeled probe
for NOPR mRNA (B) and immunohistochemical staining with anti-ALDH1L1 (A) antibody,
as indicated under "Methods". Notice the presence NOPR mRNA in the ALDH1L1-labeled
astrocytes. Specificity of both the probe (D-F) and antibodies (G-I) were investigated
accordingly. Scale bar: 10μm. Rb Serum: rabbit pre-immune serum control for rabbit antiALDH1L1, Ms Serum: mouse pre-immune serum control for mouse anti-digoxigenin.
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Figure 2.9 In vivo expression of nociceptin and NOPR in developing rat astrocytes.
Gestational

week

23,

fetal

cortical

brain

tissue

slices

were

subjected

to

immunohistochemistry using anti-GFAP (A and D), together with anti-nociceptin (B) or
anti-NOPR (E) antibodies.
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Figure 2.10 Astrocytic NOPR expression during postnatal rat brain development.
Cortical tissue slices from 2-, 5-, 9-, 13-, 18-, and 21-postnatal day (PD) rat pups were
subjected to immunohistochemistry with anti-ALDH1L1 (red) and anti-NOPR (green) to
assess astrocytic NOPR localization throughout postnatal development.

Notice that

astrocytic NOPR expression is developmentally regulated and decreases with brain
maturation. Scale bar: 10μm.
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Figure 2.11 Astrocytic NOPR expression during postnatal rat brain development.
Cortical tissue slices from 2-, 5-, 9-, 13-, 18- and 21-postnatal day (PD) rat pups were
subjected to immunohistochemistry with anti-GFAP (red) and anti-NOPR (green) to assess
astrocytic NOPR localization throughout postnatal development. Notice that astrocytic
NOPR expression is developmentally regulated and decreases with brain maturation. Scale
bar: 10μm.
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Figure 2.12 Nociceptin and NOPR are present in cultured primary human and rat
astrocytes. (A-F) Primary rat astrocytes were cultured for 24 hrs in chemically defined
medium (CDM). Immunocytochemistry was used to analyze the expression of ALDH1L1 (A
and D) together with nociceptin (B) or NOPR (E). (G-L) Primary human astrocytes were
also cultured in CDM alone for 24 hrs and similarly stained for ALDH1L1 (G and J) and
nociceptin (H) or NOPR expression (K).
ALDH1L1. Scale Bar: 50μm.
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More than 90% of cells were positive for
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Figure 2.13 Nociceptin and NOPR are expressed in cultured primary human and rat
astrocytes. (A-F) Primary rat astrocytes were cultured for 24 hrs in chemically defined
medium (CDM). Immunocytochemistry was used to analyze the expression of GFAP (A and
D) together with nociceptin (B) or NOPR (E). (G-L) Primary human astrocytes were also
cultured in CDM alone for 24 hrs and similarly stained for GFAP (G and J) and nociceptin
(H) or NOPR expression (K). More than 90% of cells in culture were positive for GFAP
labeling. Scale Bar: 50μm.
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decreases with brain maturation, following a pattern that is similar to that described above
for nociceptin brain levels (Fig. 1).

The nociceptin system regulates GLAST expression in rat and human developing
astrocytes
The findings described above pointed to a potential role of nociceptin in developing
astrocytes. Thus, we next decided to investigate this possibility by directly testing the
potential effects of this peptide in cultured cells. We first examined if the nociceptin system
was also expressed when primary rat and human astrocytes were isolated and cultured in
chemically defined medium (CDM). For this, rat (Fig. 2.12, A-F) and human (Fig. 2.12, G-L)
cultured cells were subjected to immunocytochemical analysis with anti-ALDH1L1 (A, D, G,
and J) and antibodies for nociceptin (B and H) or NOPR (E and K). The results indicated
that similar to the above in vivo observations, nociceptin and NOPR are indeed present in
both rat and human cultured astrocytes. Similar results were obtained in cell cultures
subjected to immunocytochemistry with anti-GFAP and nociceptin or NOPR antibodies
(Fig. 2.13).

As depicted in Figure 14, western blot analysis showed that incubation of the rat
astrocytes in the presence of increasing concentrations of nociceptin did not affect
expression of GFAP (Fig. 2.14A), but unexpectedly resulted in a dose-dependent increase
in the levels of the glutamate transporter GLAST (Fig. 2.14B). Important to note is that
these cultures exhibit a high molecular weight form of GLAST that has been previously
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Figure 2.14 Treatment of astrocytes with nociceptin results in a dose-dependent
increase in GLAST expression. Astrocytes isolated from 3-day-old rats were treated for
24 hrs with increasing concentrations of nociceptin. GFAP (A) and GLAST (B) expression
were evaluated using western blot analysis, using β-actin as loading control. Results are
expressed as change relative to control values and represent the mean ± SEM, n=3, *p<0.05,
**p<0.01, ***p<0.001. (C) Western blot analysis was used to determine relative GLAST
levels in total homogenates of 2-, 5-, 9-, 13-, 18-, and 21-day-old rats. Each lane was loaded
with 5ug of protein and GLAST levels are expressed as an mean ± SEM of 3 animals of each
age.
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Figure 2.15 Nociceptin treatment increases GLAST expression in cultured astrocytes.
Western blot analysis was used to determine relative GLAST levels after a 24 hr treatment
in CDM alone, 1μM nociceptin, 100nM BAN-ORL24 (NOPR-I) or 1μM nociceptin+100nM
NOPR-I. The results are expressed as change relative to control values are the mean ± SEM
from at least 3 experiments; control vs. nociceptin and NOPR-I, *p<0.05; nociceptin vs.
nociceptin + NOPR-I, # p<0.03.
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Figure 2.16 Nociceptin is synthesized and secreted by primary human and rat
astrocytes Secretion of endogenous nociceptin by cultured rat (white bars) and human
astrocytes (black bars) was assessed by dot blot analysis of medium collected from their
respective cultures after 6, 12, and 24 hrs in CDM alone. The results are the mean ± SEM
from 3 different cultures, human 24 vs. 6 hrs and rat 24 vs. 6 hrs and 12 hrs, **p<0.01.
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shown (Schlag et al., 1998; Ye and Sontheimer, 2002) to be characteristic of immature
astrocytes. Others have demonstrated that the "classical" low molecular weight GLAST is
on the other hand the predominant form that is expressed when the maturation of
astrocytes is induced by treatment with dbcAMP (Schlag et al., 1998; Duan et al., 1999;
Susarla et al., 2004; Filosa et al., 2009; Carbone et al., 2012). Importantly, a developmental
expression of these GLAST bands is also observed in vivo. As shown in Figure 2.14C,
western blot of total brain homogenates reveals that the higher molecular weight form of
GLAST predominates before PD9, an age at which the high and low molecular weight bands
appear to be present in equivalent amounts. However, after this time, the low molecular
weight band, believed to be the monomeric form of GLAST, is more prominent.
To further substantiate the specificity of nociceptin action, the cells were then cultured
in CDM alone, CDM with 1μM nociceptin, CDM with 100nM NOPR inhibitor BAN-ORL24
(NOPR-I), or CDM supplemented with a combination of both nociceptin and NOPR-I (Fig.
15). As described above, a 24-hr incubation with nociceptin resulted in a significant
elevation in GLAST expression. However, this effect was abrogated upon co-incubation
with NOPR-I, indicating that activation of NOPR is a necessary step in the nociceptindependent upregulation of GLAST (Fig. 2.15). Interestingly, comparison with control cells
showed that NOPR-I treatment itself causes a small but statistically significant decrease in
GLAST levels. Since no effects on cell viability were detected, this could be attributed to an
inhibitory effect on the action of endogenously produced nociceptin. This possibility is
supported by the observation that as already indicated above (Figs. 2.2, 2.5, 2.6, 2.9, 2.12

92

Figure 2.17. GLAST expression increases after nociceptin treatment in rat developing
astrocytes. (A-L) Immunocytochemistry with anti-GFAP (red) and anti-GLAST/EAAT1
(green) antibodies was used to evaluate GLAST/EAAT1 expression and GFAP-GLAST colocalization in cultures treated for 24 hrs with (A-C) CDM alone (D-F) 1μM nociceptin (G-I)
100nM BAN-ORL24 and (J-L) 100nM BAN-ORL+1μM nociceptin. Scale Bar: 100μm. (M)
Determination of GLAST positive cells as % of GFAP(+) cells/field. Results are the mean ±
SEM from ten fields/condition, *** p<0.001.
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Figure 2.18 GLAST expression increases after nociceptin treatment in human
developing astrocytes. Immunocytochemistry of developing human fetal astrocytes with
anti-GFAP (red) and anti-GLAST/EAAT1 (green) antibodies. Cells were incubated for 24 hrs
in (A-C) CDM alone or (D-F) CDM supplemented with 1μM nociceptin. Scale Bar: 100μm
(G) Determination of GLAST/EAAT1 positive cells as % of GFAP(+) cells/field. Results are
the mean ± SEM from ten fields/condition, *** p<0.001.

95

96

and 2.13), both rat and human in vivo and cultured astrocytes express nociceptin.
Furthermore, as depicted in Figure 2.16, analysis of medium collected from both rat and
human cells grown in CDM alone, indicate that astrocytes indeed secrete nociceptin. The
results indicated that the concentration of endogenous nociceptin released by both rat and
human astrocytes ranges from 12 to 20nM at 6 hrs to a maximal value of 50 to 80nM after
24 hrs in culture (Fig. 2.16). This information combined with the reported EC50 value for
NOPR of 90nM in neurons (Connor et al., 1996) suggests 10% saturation at 6 hours and
50% saturation of NOPR under basal culture conditions after 24 hours. Thus while the
cells indeed produce a significant amount of nociceptin the addition of exogenous peptide
is still able to further stimulate the expression of GLAST.

The stimulatory effect of nociceptin is also clearly observed when astrocytes are analyzed
by immunocytochemistry (Fig. 2.17, A-L) and the results expressed as percentage of
GFAP(+) cells that are also GLAST positive under the different culture conditions (Fig.
2.17M). About 42% of GFAP(+) cells in the nociceptin-treated cultures (Fig. 2.17, D-F)
expressed GLAST in comparison to only 18% for the control astrocytes in CDM alone (Fig.
2.17, A-C) and approximately 9-5% for those co-incubated with NOPR-I (Fig. 2.17, G-I) or
a combination of nociceptin and NOPR-I (Fig. 2.17, J-L). Furthermore, the stimulatory
effect of nociceptin on GLAST expression is not restricted to the rat cells, since a similar
result was also observed in studies using cultured fetal human astrocytes. As shown in
Figure 2.18, a significantly greater percentage of the human cells also express GLAST upon
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Figure 2.19 3H-Aspartate uptake increases in primary rat astrocytes treated with
nociceptin. (A) Aspartate uptake in primary rat astrocytes after 24 hr pre-treatment with
CDM alone (controls) (white bars) or CDM with 1μM nociceptin (black bars) was
determined using a 3H-aspartate uptake assay as described in the methods. Results are
expressed as pmol/μg/min ± SEM from at least 10 replicates/condition, *p<0.05,
***p<0.001. (B) Aspartate uptake was assessed in cell cultures after 24 hours pretreatment in CDM alone (white bars) or CDM supplemented with 1μM nociceptin (black
bars). Prior to the assay, parallel controls and nociceptin-treated cultures were in addition
pre-incubated for 10 min with either 300μM DHK or 1μM TFB-TBOA.

Results are

expressed as % change in uptake over 30 min ± SEM from at least six replicates/condition,
control vs control with TFB-TBOA and nociceptin vs. nociceptin with TFB-TBOA,
***p<0.0001.
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Figure 2.20 Endogenous nociceptin contributes to 3H-Aspartate uptake in primary
rat astrocytes. Aspartate uptake was assessed in primary rat cultures treated for 24 hrs
with CDM alone, or CDM supplemented with 100nM NOPR-I, 1μM nociceptin, or 1μM
nociceptin with 100nM NOPR-I. Results are expressed as change in uptake over 30 min ±
SEM from at least six replicates/condition. Control vs. NOPR-I, **p<0.01; control vs.
nociceptin, ***p<0.001; nociceptin vs. nociceptin with NOPR-I, ***p<0.001. Arrow 1:
aspartate uptake due to endogenously produced nociceptin. Arrow 2: aspartate uptake due
to exogenously added nociceptin.
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treatment of the cultures with nociceptin (~37%) (Fig. 2.18, D-F) when compared to those
that were incubated under basal control conditions in CDM alone (~12%) (Fig. 2.18, A-C).
Together with the previous observations in the rat cells, these findings point to a conserved
function of nociceptin in regulating GLAST expression in developing astrocytes.

The nociceptin system regulates GLAST activity
Importantly, the elevation of GLAST protein levels induced by nociceptin is indeed
accompanied by an increase in transporter activity. As depicted in Figure 2.19A, cells
exhibited increased aspartate uptake when transporter activity was assayed after a 24
hour pre-treatment with nociceptin. This uptake was not affected by treatment with the
GLT-1 selective inhibitor DHK, but was in contrast reduced to background levels by the
GLT-1/GLAST inhibitor TFB-TBOA (Fig. 2.19B).

These observations indicate that

nociceptin-induced increase in aspartate transport is indeed mediated by GLAST.

Importantly, the increase in transporter activity observed after a 24-hr pre-treatment
with nociceptin is not seen if the cells are pre-incubated with a combination of nociceptin
and NOPR-I. Important to note is that as indicated previously (Fig. 2.16D), the cultured
cells produce and secrete nociceptin. This raises the question of whether the aspartate
uptake in the control cells, pre-incubated in CDM alone, reflects a contribution of
endogenous nociceptin to GLAST expression. As shown in Figure 2.20C, support for this
possibility, stems from the observation that pre-treatment of control cells with NOPR-I
alone results in a small but statistically significant decrease in aspartate uptake (arrow 1),
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Figure 2.21 In vivo treatment with an NOPR inhibitor affects GLAST brain expression
in an age-specific manner. (A and B) Rat pups were given IP injections of BAN-ORL24 on
three timelines. Total homogenates prepared from brains collected at the end of each
injection schedule were subjected to western blot analysis for GLAST (C and D) GLAST
expression in total brain homogenates of animals injected from PD3 to PD9 (C) and PD9 to
PD14 (D).
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Figure 2.22 In vivo treatment with an NOPR inhibitor does not affect GLT-1 brain
expression in an age-specific manner. GLT-1 levels in brain homogenates from pups
injected from PD3 to PD9 (A and C) and PD9 to PD14 (B and D). The results are expressed
as change relative to control values and represent mean ± SEM from five animals, ND- not
detectable, n.s.- not significant.
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Figure 2.23. Genetic ablation of NOPR also results in reduced GLAST expression. Total
brain homogenates from 14-day-old NOPR knockout mice were subjected to western blot
analysis to evaluate expression of GLAST (A) and GLT-1 (B), using β-actin as a loading
control. Results are the represented as change relative to wild-type (WT) and are the mean
± SEM from four animals, * p<0.01.
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Figure 2.24. Mouse astrocytes also express NOPR mRNA. 5-day-old WT and NOPR KO
mouse cortical brain tissue slices were subjected to in situ hybridization using a
digoxigenin labeled probe for NOPR mRNA (B and E) or digoxigenin-labeled nonsense
deoxyoligonucleotide probe (H) and immunohistochemical staining with anti-ALDH1L1 (C,
F, and I) antibody. Notice the presence of NOPR mRNA in ALDH1L1-labeled astrocytes in
WT mice (B) and lack of NOPR mRNA in the NOPR KO animals (E) and absence of signal in
nonsense labeled sample (H). Scale bar: 10μm.
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which parallels the previously described decrease in GLAST protein levels after treatment
of cultured astrocytes with NOPR-I (Fig. 2.15). Therefore, it is possible to hypothesize that
the aspartate uptake measured after cells are pre-treated for 24 hours with nociceptin
reflects the increase in GLAST expression due to both exogenously added (arrow 2) as well
as endogenously produced nociceptin (arrow 1). Altogether, the results presented up to
this point indicated that nociceptin-dependent increases in GLAST levels are accompanied
by elevated transporter activity and these effects may be part of an autocrine loop that
contributes to glutamate homeostasis in the developing brain.

In vivo regulation of GLAST expression by the nociceptin system

The results described above raised the question of whether nociceptin effects on GLAST
expression are also observed in vivo. To investigate this problem, we focused on the first
two weeks of life which in addition to showing the highest levels of postnatal nociceptin
expression (Fig. 2.1), also represent a major time period of astrocyte proliferation and
differentiation in rodents (Mission et al., 1991; Rice and Barone, 2000). To evaluate the
role of nociceptin in vivo, rats pups were administered the blood brain barrier permeable
NOPR-I, BAN-ORL24 (1mg/kg/day), using two separate schedules (Fig. 2.21, A and B). In
the first group, pups received daily injections from PD3 to PD9 (Fig. 2.21A), a time period
that includes the peak of both astrocyte development and postnatal nociceptin expression.
A second group of animals was administered the NOPR-I from PD9 to PD14 (Fig. 2.21B), a
window that does not include the peak of astroglial development but encompasses other
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events such as the start of myelination. Comparison with vehicle-injected control pups,
indicated that GLAST expression was significantly decreased in the brains of animals
treated with NOPR-I from PD3 to PD9 (Fig. 2.21C). However, no significant differences
between controls and NOPR-I-treated rats were detected when the inhibitor was
administered between PD9 to PD14 (Fig. 2.21D). Altogether, these results point to a role
of the nociceptin system that is restricted to the first 9-10 days of postnatal rat brain
development. It is during this time that the prominent higher molecular weight band on the
western blot decreases and the presence of the monomeric weight band increases (Figure
2.14C). Interestingly, the changes seen in GLAST expression at PD9 occur in the lower
molecular weight band. The possible reasons for this will be further discussed later.
In contrast, no effects of NOPR-I were detected when the same animals were examined for
the brain expression of GLT-1 (Fig. 2.22). Notice that only background levels of GLT-1 are
observed between PD3 and PD9 (Fig. 2.22C) as the expression of this glutamate
transporter is known to begin after the first postnatal week (Ullensvang et al., 1997;
Schreiner et al., 2014). Moreover, a role of the nociceptin system in controlling GLAST
expression is also supported by the observation that NOPR knockout mice exhibit
decreased GLAST brain levels (Fig. 2.23A). To further substantiate these observations we
determined GLAST levels in wild-type (WT) and NOPR KO mice. Analogous to the rat and
human cells, mouse astrocytes also express NOPR mRNA (Fig. 2.24, A-C), which is clearly
absent in the NOPR KO animals (Fig. 2.24, D-F). Furthermore, similar to the observations
on GLT-1 expression in the NOPR-I injected pups (Figs. 2.22), the apparently normal GLT1.
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Figure 2.25 A number of different kinases were investigated for a possible role in the
nociceptin-mediated expression of GLAST. Immunocytochemical analysis of GLAST
expression in rat astrocytes was carried out after treatment with inhibitors of various
kinases.

LY=LY294002, PI-3K inhibitor; JAKi=JAK Inhibitor I, Janus kinase inhibitor;

Rapa=Rapamycin, mTOR inhibitor; PD=PD98059, ERK ½ inhibitor; SB=SB202190,
p38MAPK inhibitor; SQ=SQ22536, adenylyl cyclase inhibitor; Go=Go6983, PKC inhibitor;
KT=KT5720, PKA inhibitor; KN=KN93, CamKII inhibitor. The bar graph shows the number
of GLAST positive cells as a % of the GFAP(+) cells/field under each condition. Results are
the mean ± SEM from 10 fields/condition.
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Figure 2.26 Involvement of PI-3K/AKT, in the nociceptin-dependent upregulation of
GLAST expression. Astrocyte cultures were first pre-incubated for 2 hrs in DMEM-F12
alone; and then for increasing times (0-60 min) in CDM alone, CDM with 1μM nociceptin,
CDM with 30μM LY294002 (LY) or CDM with 1μM nociceptin and 30μM LY. Cell lysates
were then subjected to western blot analysis with an antibody against phosphorylated AKT
(pAKT). The results are the mean ± SEM from 3 different cultures; control vs. nociceptin at
60 min, ***p<0.001.
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Figure 2.27. The nociceptin dependent upregulation of GLAST is also mediated by
mTOR and JAK signaling complexes. (A) Immunocytochemistry was used to evaluate
GLAST expression in rat astrocytes after a 24 hr treatment with CDM alone, or CDM
supplemented with one of the following: 1μM nociceptin, 30μM LY294002 (LY), 1μM
nociceptin and 30μM LY 25nM Rapamycin (Rapa), 1μM nociceptin and 25nM Rapa, 1μM
JAK Inhibitor I (JAK-I), or 1μM nociceptin and 1μM JAK-I. The bar graph shows the number
of GLAST positive cells as a % of the GFAP(+) cells/field under each condition. Results are
the mean ± SEM from twelve fields/condition, control vs. nociceptin ***p<0.001. (B)
Astrocytes treated for 24 hrs in the conditions listed above, were subjected to western blot
analysis for GLAST. GLAST levels in the bar graph are expressed as change relative to the
control values. The results are the mean ± SEM, n=3, control vs. nociceptin ***p<0.001.
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Figure 2.28 JAK acts upstream of PI-3K in the nociceptin-mediated modulation of
GLAST expression. Astrocyte cultures were first pre-incubated for 2hrs in DMEM-F12
alone; and then for increasing times (0-60 min) in CDM alone, CDM with 1μM nociceptin,
CDM with 1μM JAK-I or CDM with 1μM nociceptin and 1μM JAK-I. Cell lysates were then
subjected to western blot analysis for pAKT. The results are the mean ± SEM from 3
different cultures; control vs. nociceptin at 60 min, ***p<0.001.
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levels in NOPR KO animals (Fig. 2.23B), supports the notion that nociceptin effects are
restricted to GLAST expression. Altogether, these results further substantiate the notion
that nociceptin signaling plays a crucial role in controlling GLAST expression in developing
astrocytes

The stimulation of GLAST expression by nociceptin involves a PI-3K/AKT, mTOR and
JAK- mediated pathway
We next thought to investigate the molecular mechanisms that regulate GLAST expression
downstream of NOPR activation. Testing of a number of specific enzyme inhibitors (data
not shown) determined that neither ERK, PKA, PKC, p38MAPK, CamKII, NOPR adenylate
cyclase play any significant role in the nociceptin-dependent up-regulation of GLAST
(Figure 2.25). However, significant results were obtained when investigating the role of a
PI-3K/AKT-dependent pathway. In these studies, cells were pre-incubated for 2 hrs in
DMEM-F12 medium alone to downregulate potential previous signaling induced by
endogenously produced nociceptin. As shown in Figure 2.26, incubation in CDM alone
elicits Ser473 AKT phosphorylation, an action most likely resulting from the presence of
insulin which is known to stimulate AKT activation in the majority of cell types. However,
only treatment with nociceptin-containing CDM resulted in sustained AKT phosphorylation
during the entire 60-min incubation.

This nociceptin-dependent stimulation of AKT

phosphorylation is abolished by co-incubation of the cells with LY294002, an inhibitor of
PI-3K, the kinase that phosphorylates AKT. Furthermore, the role of a PI-3K/AKT pathway
downstream of NOPR activation is substantiated by the finding that PI-3K inhibition indeed
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Figure 2.29 Proposed signaling pathway of nociceptin-mediated GLAST expression.
The effects of different inhibitors (Fig 2.22-2.24) indicate that nociceptin effects on GLAST
expression are mediated by a signaling cascade that involve the interaction of several
kinase systems, including PI-3K/AKT, mTOR, and JAK. Solid lines represent interactions we
have found.

Dashed arrows represent possible interactions that require further

investigation.
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blocks the capacity of nociceptin to increase GLAST expression, as shown by both
immunocytochemical staining (Fig. 2.27B) and western blot analysis (Fig. 2.27C) of the
cells. In addition, as shown in Figure 2.27, the stimulatory effect of nociceptin is also
blocked by rapamycin, an inhibitor of the mTOR kinase complex that is a key regulator
frequently downstream of PI-3K/AKT activation. Treatment with rapamycin abolishes the
capacity of nociceptin to increase both the percentage of astrocytes expressing GLAST (Fig.
2.27A) as well as the elevation of GLAST levels detected by western blotting (Fig. 2.27B).
Furthermore, the stimulatory effect of nociceptin on GLAST expression was also blocked by
the Janus kinase (JAK) inhibitor I (Figs. 2.27, A and B). Moreover, this inhibitor also
blocks the sustained nociceptin-dependent stimulation of AKT phosphorylation observed
at 60 min (Fig. 2.28), suggesting that JAK acts upstream of PI-3K. This is particularly
interesting as a JAK/STAT pathway was implicated in regulating GLAST expression in a
model of perinatal hypoxia (Raymond et al., 2011). Furthermore, JAK/STAT signaling is
believed to control the differentiation of Nestin(+) pluripotent cells into GFAP(+)
astrocytes (Sriram et al., 2004; Gautron et al., 2006). While the precise interaction of JAK
and PI-3K/AKT downstream of NOPR activation remains to be investigated, altogether
these observations show that nociceptin regulates GLAST expression in developing
astrocytes by a complex mechanism that involves PI-3K/AKT, mTOR and JAK activation
(Fig. 2.29).
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CHAPTER 3

DISCUSSION
The studies undertaken in this investigation uncovered a novel role for the
nociceptin system during brain maturation. Our in vitro and in vivo findings showed that
nociceptin plays a conserved role stimulating the expression of the glutamate transporter
GLAST/EAAT1 in both rodent and human developing astrocytes. This regulatory effect is
mediated by NOPR and the downstream participation of a complex signaling cascade that
involves the interaction of several kinase systems, including PI-3K/AKT, mTOR and JAK.
Furthermore, the observation that these cells also produce and secrete nociceptin suggests
the existence of a nociceptin-mediated autocrine loop crucial to the regulation of GLAST
expression and glutamate homeostasis in developing astrocytes. Together with our
previous findings in oligodendrocytes (Eschenroeder et al., 2012), the present results
further implicate the nociceptin system as a critical regulatory player during CNS formation
and brain maturation.

Nociceptin effects on GLAST expression exhibit temporal specificity
An important observation of these studies is the specificity of timing for these nociceptin
effects. The in vivo findings (Fig 2.2-2.12) indicated that, overlapping with the temporal
elevation of nociceptin brain concentration (Fig. 2.1) and astroglial NOPR expression
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Figure 3.1 Nociceptin-mediated effects on GLAST occur within the first 9-10
postnatal days. The green window represents the time period in rats during which
nociceptin exerts an effect on GLAST expression. The peak of gliogenesis and
synaptogenesis also occur during this critical time period.
the equivalent developmental period in humans.
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The pink window represents
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(Figs. 2.10 and 2.11), the capacity of nociceptin to increase GLAST levels in the rat brain is
restricted to a developmental window that encompasses the first 9-10 days of postnatal life
(Fig. 3.1). This observation is particularly significant because this postnatal stage in
rodents is equivalent to the third trimester in humans (Workman et al., 2013), a time
period during which we have shown that developing human astrocytes express NOPR
(Figs. 2.3, 2.5, 2.7 and 2.9). Importantly, this maturational stage of the mammalian brain
includes the formation of a major number of glutamatergic synapses, a crucial
developmental event that immediately follows the rapid generation of astrocytes (Miller
and Gauthier, 2007) and occurs at a time at which astrocytic GLAST/EAAT1 is still the
dominant transporter responsible for local control of glutamate levels (Danbolt, 2001)
(Fig. 3.1).

The specificity of nociceptin effects on GLAST expression further emphasizes the
differences between GLAST and GLT-1 regulation
Several lines of evidence indicate that GLAST and GLT-1 expression are subjected to
different regulatory mechanisms. As discussed above, our findings demonstrated that
nociceptin specifically stimulates GLAST expression at the early stages of brain
development (Fig 2.21). Based on this observation, it is possible to speculate that this
nociceptin-dependent mechanism is a major determinant for the differential pattern of
expression exhibited by GLAST and GLT-1. GLAST expression is easily detected in the
newborn pups. However, in agreement with the observations from other laboratories
(Furuta et al., 1997; Ullensvang et al., 1997; Schreiner et al., 2014), our present studies
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were unable to detect GLT-1 expression in the younger group of pups (postnatal days 3 to
9) (Fig. 2.22C). Interestingly, while GLT-1 is readily detectable in the brain of older
animals, no significant differences in GLT-1 expression were observed at any age group
between controls and NOPR inhibitor-treated rats (Fig. 2.22) or between wild-type and
NOPR KO mice (Fig. 2.23); indicating that, in contrast with GLAST, GLT-1 expression is not
regulated by the nociceptin system. Our findings add to results from others demonstrating
that GLAST and GLT-1, which have almost equal affinities for glutamate and similar
structures, are on the other hand differentially regulated and maintain unique expression
patterns both in the developing and in the adult brain (Wadiche et al., 1995; Rothstein et
al., 1996; Bar-Peled et al., 1997; Furuta et al., 1997; Ullensvang et al., 1997; Schlag et al.,
1998; Gegelashvili et al., 2000; Perego et al., 2000; Danbolt, 2001; Mim et al., 2005;
Schreiner et al., 2014).
Previous studies from other laboratories provided evidence for the existence of
important mechanisms that also play a crucial role in this regulation. As depicted in Fig.
3.1, GLAST expression in the rat brain begins around E11 and continues to increase
throughout synaptogenesis. In remarkable contrast, GLT-1 is not detected until the peak of
developmental synaptogenesis that occurs significantly later, approximately eight days
after birth (Lehre et al., 1995; Ullensvang et al., 1997). In spite of the different onset of
GLAST and GLT-1 appearance, their temporal expression patterns coinciding with
synaptogenesis (Lehre et al., 1995; Ullensvang et al., 1997) and the observed reduction in
transporter levels that occurs after denervation (Levy et al., 1995), raised the possibility
that soluble factors released from neurons, may play a regulatory role on both GLAST and
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GLT-1 levels. In support of this idea, studies with either neuron-astrocyte co-cultures
(Swanson et al., 1997; Schlag et al., 1998) or cultured astrocytes treated with neuronconditioned medium (NCM) (Swanson et al., 1997), displayed effects on GLT-1 and GLAST
expression. However, both studies showed a very large induction of GLT-1 expression but a
much smaller increase in GLAST levels. Of course it is temping to hypothesize that one of
the neuronal factors stimulating GLAST expression could be nociceptin. Regardless of the
mechanisms, those observations and our present findings provide strong evidence for the
existence of different regulatory systems that specifically control GLAST and GLT-1
expression.

Signaling molecules mediating the stimulation of GLAST expression downstream of
NOPR activation
Our results indicated that the modulation of GLAST expression by nociceptin and NOPR
activation involves the PI-3K (Fig 2.26-2.29) and results in sustained AKT phosphorylation
(Fig. 2.26). Interestingly, a PI-3K mediated pathway may also participate in the regulation
of GLAST levels induced by glutamate-dependent activation of metabotropic receptors.
Involvement of these glutamate receptors in the control of GLAST expression was
demonstrated in studies indicating that exposure of astrocytes to the mGluR2/3 agonist
DCG-IV results in elevated GLAST protein (Gegelashvili and Schousboe, 1997; Gegelashvili
et al., 2000; Aronica et al., 2003; Hazell et al., 2003), as well as the observation that mGluR3
KO mice exhibit decreased GLAST levels (Lyon et al., 2008). Importantly, studies from Lin
et al, showed that the mGluR-dependent increase in GLAST expression requires signaling
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cascades that include PI-3K, ERK and NF-κB (Lin et al., 2014). Thus, participation of the PI3K in the regulation of GLAST levels induced by both NOPR and mGluR3 activation, raises
the possibility of a "coordinated" effect of these two receptor-mediated pathways on
glutamate homeostasis. Therefore, it would be interesting to investigate GLAST expression
in both a prepronociceptin KO mouse after mGluR3 agonist treatment, as well as the effect
of nociceptin on GLAST expression in a mGluR3 KO animal. Furthermore, our studies also
showed that GLAST expression in response to NOPR activation involves JAK (Fig 2.27 and
2.28), and inhibition of this kinase blocks the nociceptin-mediated phosphorylation of AKT
(Fig. 2.28), a critical step in our proposed signaling cascade (Fig 2.29). AKT activation by
JAK in astrocytes was also demonstrated to occur as a result of JAK-dependent
phosphorylation of PI-3K during the induction of the chemokine (C-C motif) ligand 5
protein (CCL5) by HIV-1 Tat (Nookala et al., 2013).
While our present results already identified a role for JAK and the PI-3K in mediating
AKT phosphorylation downstream of NOPR activation, it is possible to hypothesize that
these two kinases may also play an additional function within the this cascade responsible
for increased GLAST levels. This is because studies in HEK293 and SH-SY5Y cells which
indicated that JAK and PI-3K, can respectively phosphorylate and activate the transcription
factors STAT (Wu et al., 2003) and NF-κB (Donica et al., 2011) in response to NOPR
activation. Furthermore, the GLAST gene promoter includes binding sites for STAT and NFκB (Unger et al., 2012; Karki et al., 2015), making it reasonable to hypothesize that both
transcription factors could then participate in the nociceptin-dependent regulation of
GLAST levels.
131

It is also important to point out that our results indicate that the signaling pathway
triggered by nociceptin additionally involves the mTOR kinase (Fig. 2.27). The role of
mTOR here may be multifunctional because in addition to its well known function as a
regulator of translation, mTOR has been shown to increase STAT3 activation by
phosphorylation of STAT3 at Ser 727 (Yokogami et al., 2000; Wang et al., 2008).

Figure 3.2. Proposed mechanism of nociceptin-mediated GLAST expression. Solid
arrows represent interactions that we have found. Dashed arrows represent hypothetical
interactions and transcription factors that might also participate in this signaling cascade.
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Further studies are necessary to test this possibility and the potential role of these and
other transcription factors in mediating nociceptin effects in the developing astrocytes.

Glutamate functions in the developing brain underscore the importance of a role for
nociceptin in glutamate homeostasis
It is reasonable to speculate that the novel function of nociceptin discovered in this
thesis project is critical for normal CNS development. This is because the embryonic and
early postnatal GLAST/EAAT1 function is fundamental beyond protection from glutamateinduced cytotoxicity and regulation of glutamatergic activity, as results from different
laboratories pointed to glutamate as a pivotal regulator of crucial aspects of brain
maturation. Glutamate was shown to control the proliferation and survival of neural
progenitors through both interactions with glutamate receptors as well as paracrine
actions that influence the expression of neurotrophic factors (Zafra et al., 1991; LoTurco et
al., 1995; Luk et al., 2003; Luk and Sadikot, 2004; Brazel et al., 2005; Mattson, 2008;
Jansson and Akerman, 2014).

Moreover, blocking ionotropic glutamate receptors

decreases the rate of neuronal migration and glutamate concentration gradients in the
developing brain serve as chemoattractants, stimulating neurons to migrate toward their
final location (Komuro and Rakic, 1993, 1998; Behar et al., 1999). Activation of glutamate
receptors by subtoxic levels can also result in opening of voltage-dependent Ca2+ channels,
which subsequently suppresses growth cone function and dendritic outgrowth (Mattson et
al., 1988; Voss et al., 2007; Whitney et al., 2008; Jansson et al., 2013); and both
metabotropic and ionotropic glutamate receptors are thought to play an important role in
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the cell contact-mediated suppression of sprouting that occurs prior to the establishment
of action potential activity (Miskevich et al., 2002). Direct activation of NMDA, AMPA and
KA receptors by glutamate increases both branching and length of process outgrowth
(Komuro and Rakic, 1993; Voss et al., 2007; Whitney et al., 2008; Jansson et al., 2013), and
studies from Kwon and Sabatini (Kwon and Sabatini, 2011) showed that glutamate is also
able to induce the de novo growth of functional spines in the developing cortex.
It is important to note, that together with glutamate, early brain development is
characterized by the presence of an additional excitatory molecule, GABA, which is on the
other hand the main inhibitory neurotransmitter in the mature CNS (Ben-Ari et al., 1989;
Ben-Ari, 2002; Represa and Ben-Ari, 2005). GABA early excitatory signals have been shown
to act synergistically with glutamate to play a role in proliferation (Luk and Sadikot, 2001;
Luk et al., 2003), neurite outgrowth (Spoerri, 1988), migration (Behar et al., 1998; Fueshko
et al., 1998; Komuro and Rakic, 1998; López-Bendito et al., 2003) and synaptogenesis
(Spoerri, 1988). Both GABA and glutamate effects are concentration-dependent, and a
large body of evidence suggests that glutamatergic/GABAergic dysfunction during this
early time period can be detrimental, further supporting the need for strict glutamate
regulation during this developmental window (Khazipov et al., 2004; Chao et al., 2010;
Ramamoorthi and Lin, 2011; Smith-Hicks, 2013). This possibility further underscores the
role of nociceptin as a regulator of astrocytic GLAST/EAAT1 expression and the potential
importance of this function in controlling glutamate homeostasis during brain
development.
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Potential functions of elevated nociceptin expression of during early postnatal brain
development
The results presented in this thesis raise the question of whether alterations in
nociceptin system activity may disrupt glutamate-dependent processes during brain
maturation, in particular those that could result in abnormal synapse plasticity and
connectivity. While the roles of nociceptin in the early postnatal and embryonic brain are
poorly understood, the significantly higher level of nociceptin expression during this
critical period makes the nociceptin system an interesting target for neurodevelopmental
studies (Fig. 2.1).

Early work on the nociceptin system showed that expression of

prepronociceptin is transiently upregulated during neuronal differentiation and correlates
with the appearance of dendrites (Saito et al., 1995). Further research indicated that
overexpression of prepronociceptin, incubation of neurons with factors that upregulate
prepronociceptin mRNA, or treatment with exogenously added nociceptin all showed an
increase in neurite outgrowth (Saito et al., 1995, 1996, 1997; Sirianni et al., 1999; Zaveri et
al., 2006). More recently, our laboratory showed that the timing of oligodendrocyte
differentiation, a key developmental event, can be altered by activation of NOPR by
buprenorphine, an opioid analogue used in the treatment of pregnant opioid addicts
(Eschenroeder et al., 2012).
Furthermore, a number of different studies have shown that NOPR KO animals exhibit a
variety of abnormal responses; including those involved in spatial memory and learning
(Noda et al., 2000), feeding behavior and neuronal excitability (Koizumi et al., 2009;
Farhang et al., 2010) as well as responses to drug effects (Rizzi et al., 2000; Ueda et al.,
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2000; Mamiya et al., 2001; Sakoori and Murphy, 2004, 2009; Chung et al., 2006; Marquez et
al., 2008, 2013, Kallupi et al., 2013, 2017). While these effects have not been connected to
developmental problems, many of the abnormal responses seen in prepronociceptin and
NOPR KO animals are similar to those seen in models of pre- and early postnatal opioid
exposure (Yanai et al., 1992; Steingart et al., 2000; Velíšek et al., 2000; Šlamberová et al.,
2001, 2004, 2005; Che et al., 2005; Sarkaki et al., 2008; Wang and Han, 2009; He et al.,
2010; Jiang et al., 2011).
It remains to be determined whether such findings could be solely explained by direct
effects of nociceptin on the neuronal cells, or might also reflect among other possibilities,
an underlying alteration in network connectivity resulting from early defects in glutamate
homeostasis and brain development.

Functional consequences of glutamate and GLAST/EAAT1 dysfunction during early
CNS development
It is believed that glutamatergic dysfunction during this critical window of brain
formation may later contribute to the etiology of a number of neurodevelopmental
disorders such as schizophrenia, autism, and epilepsy (Keshavan et al., 1994; Ohrmann et
al., 2005; Tebartz Van Elst et al., 2005; Choudhury et al., 2012). Different models of epilepsy
have shown elevated resting brain levels of glutamate, as well as increased glutamate
concentrations immediately prior to seizures (Janjua et al., 1992; During and Spencer,
1993; Ferrie et al., 1999). Furthermore, seizures during early postnatal development in
rats not only increase the likelihood of later seizures but also influence the overall
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development of the brain, including the formation of excitatory versus inhibitory synapses,
as well as expression of mGluRs and GABA receptors (Zhang et al., 2004a; b; Epsztein et al.,
2006).
Significant support for the need of strict regulation of glutamate levels during brain
development stems from studies in glutamate transporter KO animal models. GLT-1-/- mice
are prone to spontaneous lethal seizures (Tanaka et al., 1997), and GLAST-/- animals show
prolonged spontaneous seizures and experienced more severe induced seizures (Tanaka et
al., 1997; Watase et al., 1998; Watanabe et al., 1999; Jen et al., 2005). Therefore, the ability
of nociceptin to increase GLAST expression and subsequent glutamate uptake may
represent a potential target for the treatment of epilepsy.
Nevertheless, while it is clear that GLAST and GLT-1 play a role in animal models of
epilepsy, the information in humans is controversial.

There have been a number of

contradictory results regarding the expression levels of these transporters in human
epilepsy.

There are studies that showed a down regulation of EAAT1 and EAAT2 levels

(Mathern et al., 1999; Proper et al., 2002; Sarac et al., 2009), as well as others that reported
no changes in transporter expression (Tessler et al., 1999; Eid et al., 2004). It is worth
mentioning that these studies in humans did not assess the function or localization of these
transporters, merely their overall expression levels.
However, strong support for a protective role of EAAT1 in epilepsy was provided by the
finding of a mutation in the SLC1A3 gene encoding EAAT1 in members of a family suffering
of episodic ataxia, seizures, and migraines (de Vries et al., 2009). Moreover, expression of
the mutated transporter protein in COS7 cells indeed indicated dramatically reduced
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glutamate uptake, an important observation that further emphasizes the role of glutamate
control in epilepsy (de Vries et al., 2009).
Therefore, the effects of nociceptin on astroglial GLAST/EAAT1 expression as shown by
the observations presented in this thesis, raise the question of whether nociceptin plays a
role in epilepsy. Several lines of evidence suggest that this may be the case. However, it is
important to emphasize that conclusions regarding nociceptin and epilepsy varied
according to the used animal model. Many of the positive roles of nociceptin were shown in
a kindling model of chronic epilepsy where as negative effects where observed in models of
single induced seizures like the kainic acid and PTZ models.
Studies using a kindling model of chronic epilepsy, showed nociceptin administration
failed to stop or shorten fully kindled seizures but it was able to significantly delay kindling
development, suggesting that nociceptin and NOPR may limit the spread of
hyperexcitability through the hippocampus (Gutiérrez et al., 2001; Carmona-Aparicio et al.,
2007). The depression of glutamatergic transmission mentioned earlier (see Opioids and
synaptic transmission, Introduction, page 42) may be one mechanism by which nociceptin
can limit the spread of hyperexcitability in a chronic model of epilepsy.
In remarkable contrast, other studies showed that mice treated with an NOPR antagonist
and PPN knockout mice exhibited less susceptibility for kainic-acid induced events,
suggesting a role for nociceptin in the generation or amplification of seizures (Bregola et
al., 2002a; b; Aparicio et al., 2004).

Therefore, the possibility of a positive role of

nociceptin in controlling GLAST levels in epilepsy is difficult to assess at this moment as
studies in animal models indicated contradictory results pointing to both protective
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(Gutiérrez et al., 2001; Carmona-Aparicio et al., 2007; Bayrakdar et al., 2013) as well as
permissive (Bregola et al., 2002a; b; Binaschi et al., 2003; Aparicio et al., 2004) roles of the
nociceptin system in this disease.

Nevertheless, one could argue that the increase in

nociceptin levels in epileptic subjects could result in a compensatory rise in the level of
GLAST to protect the brain from further excitotoxic effects of glutamate.
Together, these results combined with the evidence for a role for GLAST/GLT-1 in
epilepsy, and those presented in this thesis suggest that there may be a role for nociceptin
modulation of glutamate transporters and therefore glutamate in the induction and
propagation of seizures. However, further investigation is necessary to clarify whether the
different disease outcomes observed in the studies described above represent nociceptindependent changes in transporter expression, transporter function, or a response to
neuronal loss (Devinsky, et al, 2013; Steinhauser et al, 2015).

Nociceptin and GLAST in other cell types
Interestingly, nociceptin may also regulate GLAST levels in another glial cell type. GLAST
is also expressed in oligodendrocytes and their precursors (Domercq and Matute, 1999;
Pitt et al., 2003; DeSilva et al., 2009). Furthermore, there is evidence to suggest that GLAST
activation plays an important role in oligodendrocyte maturation (Martinez-Lozada et al.,
2014). The present findings in astrocytes, together with our previous results indicating the
presence of NOPR in developing oligodendrocytes (Eschenroeder et al., 2012) raise the
possibility that nociceptin may also play a role regulating GLAST expression in these glial
cells. Studies are in progress to investigate this possibility and the extent to which
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nociceptin-dependent regulation of oligodendroglial GLAST may play a role in controlling
developmental myelination.

Conclusion
The in vitro and in vivo results presented in this thesis show that nociceptin can
influence the expression of the astrocytic glutamate transporter GLAST, the main glutamate
transporter expressed in early brain maturation. This points to a role for nociceptin in the
developing brain specifically by contributing to glutamate homeostasis. This is important,
as glutamate has been shown to have concentration-dependent effects on a number of
different neurodevelopmental events including neuronal migration and neurite outgrowth.
These functions underscore the importance of the nociceptin-mediated expression of
GLAST as a regulator of glutamate levels in the developing brain.

Furthermore, the

presence of NOPR in a number of different cells types in the maturing CNS and the
significantly higher levels of nociceptin expression during a critical development window
makes this system an interesting target for future neurodevelopmental studies.
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